Skip to main content
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2017 Jan 30;8:22. doi: 10.3389/fphar.2017.00022

Immunosuppressive Effects of Natural α,β-Unsaturated Carbonyl-Based Compounds, and Their Analogs and Derivatives, on Immune Cells: A Review

Laiba Arshad 1, Ibrahim Jantan 1,*, Syed Nasir Abbas Bukhari 1, Md Areeful Haque 1
PMCID: PMC5277008  PMID: 28194110

Abstract

The immune system is complex and pervasive as it functions to prevent or limit infections in the human body. In a healthy organism, the immune system and the redox balance of immune cells maintain homeostasis within the body. The failure to maintain the balance may lead to impaired immune response and either over activity or abnormally low activity of the immune cells resulting in autoimmune or immune deficiency diseases. Compounds containing α,β-unsaturated carbonyl-based moieties are often reactive. The reactivity of these groups is responsible for their diverse pharmacological activities, and the most important and widely studied include the natural compounds curcumin, chalcone, and zerumbone. Numerous studies have revealed the mainly immunosuppressive and anti-inflammatory activities of the aforesaid compounds. This review highlights the specific immunosuppressive effects of these natural α,β-unsaturated carbonyl-based compounds, and their analogs and derivatives on different types of immune cells of the innate (granulocytes, monocytes, macrophages, and dendritic cells) and adaptive (T cells, B cells, and natural killer cells) immune systems. The inhibitory effects of these compounds have been comprehensively studied on neutrophils, monocytes and macrophages but their effects on T cells, B cells, natural killer cells, and dendritic cells have not been well investigated. It is of paramount importance to continue generating experimental data on the mechanisms of action of α,β-unsaturated carbonyl-based compounds on immune cells to provide useful information for ensuing research to discover new immunomodulating agents.

Keywords: α, β-unsaturated carbonyl-based compounds; curcumin; chalcone; zerumbone; immune cells; immunosuppressive effects

Introduction

The immune system is the body's complex and pervasive defense system which maintained the integrity of the body and protects it from microbial invasion. It refers to organization of immune cells and specialized immune molecules that have evolved to mediate resistance to infections. The immune system can be categorized into two major divisions i.e., innate immune system and adaptive immune system. The innate immune system refers to non-specific immunity as it is destined to attack any foreign particle invading the body and hence serve as primary defense for the body. Neutrophils, macrophages, and dendritic cells are the central players of innate immunity. Contrary to this, adaptive or acquired immunity produces a specific effect in response to an antigen and reserves the feature of immunological memory that distinguishes it from the aforementioned response. The members of acquired immunity involve majorly T cells and B cells (Lee et al., 2015). In healthy organism, the immune system and the adequate redox balance of immune cells maintain homeostasis within the body. The failure to maintain the balance may lead to impaired immune response and hence an abnormal immune system (Ilangkovan et al., 2015). Most of the immune system disorders cause abnormally low activity or over activity of the immune cells. In cases of immune system over activity, the body attacks and damages its own tissues referring to acquired immune system reaction (autoimmune diseases) while immune deficiency diseases decrease the body's ability to fight invaders, causing vulnerability to infections. Among the most common diseases are rheumatoid arthritis, type1 diabetes, systemic lupus erythematosus, tuberculosis, and atherogenesis. The autoimmune destruction of the pancreatic β cells within the islets of Langerhans results in the progression of type 1 diabetes (Mehrotra et al., 2013).

The word immunomodulation circles around the concept of reorganizing the immune system to achieve the therapeutic benefit. The aim of immunomodulators or immunotherapy is to modify the immune response according to pathological condition. Generally, there are two clinical situations when the immune system are required to be managed i.e., when the immune response is abnormally decreased (immunodeficiency) e.g., cancer, hepatitis, HIV and tuberculosis or increased like diabetes, arthritis, lupus, eczema, and multiple sclerosis (autoimmunity). In case of immunodeficiency, a therapy that particularly boosts up the immune response called immunostimulants is desired while immunosuppressant abolished the overactive immune system. Augmentation of the immune response is desirable to prevent infection in states of immunodeficiency or in case of overactive immune system. Immunoadjuvants is another term used nowadays, are specific immune stimulators which enhance the efficacy of vaccine (Gea-Banacloche, 2006). Over many decades, many natural, or synthetic immunomodulators are being used for managing immune disorders. This review is to provide updated overview of specific immunomodulatory effects of the most important and widely studied natural products containing α,β-unsaturated carbonyls, i.e., curcumin (1), chalcone (2), and zerumbone (3). The activities of these natural products and their analogs and derivatives on different types of immune cells of the innate and adaptive immune systems have been comprehensively discussed.

Natural α,β-unsaturated carbonyl-based compounds

α,β-Unsaturated carbonyl-based compounds refers to such structures possessing α,β-carbonyl moieties. In such compounds the carbon-carbon double bond and carbon-oxygen double bond are segregated by only one carbon-carbon single bond i.e., double bonds are conjugated. These conjugations not only give the properties of the functional group attached but also give some other properties to the compounds. Figure 1 illustrates the general structure of α,β-unsaturated carbonyl-based compounds. These compounds are considered to be the most reactive substructures of natural products or synthetic molecules. The reactivity of these groups owes a diverse array of pharmacological activities. The most important and widely studied α,β-unsaturated carbonyl-based compounds include the natural products, curcumin (1), zerumbone (2), chalcone (3), and their analogs and derivatives. The structures of curcumin, chalcone, and zerumbone are shown in Figure 2. In fact one-sixth of the currently known natural products contain these potentially reactive substructures (Rodrigues et al., 2016).

Figure 1.

Figure 1

General structure of α,β-unsaturated carbonyl-based compounds.

Figure 2.

Figure 2

Chemical structures of natural α,β-unsaturated carbonyl-based compounds.

Curcumin (1), the active principle of turmeric, is a hydrophobic polyphenol mainly isolated from the rhizomes (turmeric) of Curcuma longa (Anand et al., 2008). Chemically, it is a bis-α,β-unsaturated β-diketone composed of two aromatic rings joined together by two carbonyl groups. Despite the fact that curcumin is a multi-targeting agent and safer at higher doses, poor bioavailability, and solubility is still a point at issue for the researchers. To overcome this problem, scientists adopted a number of strategies including formulation of curcumin with adjuvant like piperine, curcumin-based drug delivery system, and structural modification of curcumin (Anand et al., 2007). These approaches have not yet achieved the desired therapeutic purpose but somewhat improved the pharmacokinetic profile of curcumin. The curcumin analogs were synthesized in a number of different ways either preserving the β-diketone moiety or removing it. Previous studies reported different laboratory methods involving multiple types of catalysts for the synthesis of curcumin-like structures but the most common method was found to be a Claisen–Schmidt condensation reaction, between a ketone and aldehyde in the presence of a polar solvent (Anand et al., 2008).

Zerumbone (2), (2E,6E,10E)-2,6,9,9-tetramethylcycloundeca-2,6,10-trien-1-one, a crystalline monocyclic sesquiterpene, is mainly isolated from the rhizomes of shampoo ginger (Zingiber zerumbet). Zerumbone was isolated for the first time in 1960 and structurally elucidated in 1965 (Dev, 1960; Damodaran and Dev, 1965). It contains α,β-unsaturated carbonyl moiety along with 3 double bonds, one at C-2 and the rest at C-6 and C-9 positions. Chalcone (3) is a member of flavonoid family with a 1, 3-diphenyl-2-propen-1-one skeleton. Analogous to curcumin, the structure of chalcone consists of two aromatic rings linked by a three carbon α,β-unsaturated carbonyl system. Chalcone and chalcone-based derivatives can be obtained using variety of laboratory methods and schemes. Numerous lines of evidence suggest that acid or base catalyzed aldol condensation or Claisen–Schmidt condensation of acetophenones with aromatic aldehydes are among the most conventional methods (Datta et al., 1971; Makrandi and Kumar, 2004).

Previous studies have indicated that these natural α,β-unsaturated carbonyl compounds and their analogs and derivatives exhibited a wide range of biological activities. A number of studies have showed that zerumbone, chalcone derivatives and curcumin analogs exerted immunomodulatory role (Feng et al., 2005; Magerramov et al., 2006; Keong et al., 2010; Bukhari et al., 2012, 2013b, 2014a; Lal et al., 2012). Likewise, antioxidant, anti-inflammatory, antiviral, antibacterial, antifungal, and antitubercular activities have been exhibited by these compounds (Lin et al., 2002; Murakami et al., 2002, 2004; Batovska et al., 2007; Sivakumar et al., 2007; Tomar et al., 2007; Trivedi et al., 2007; Chiaradia et al., 2008; Chien et al., 2008; Sulaiman et al., 2010; Jantan et al., 2012; Du et al., 2013; Ou et al., 2013; Bukhari et al., 2013a; Ahmad et al., 2014; Chen et al., 2014; Goodarzi et al., 2014). Recently, some studies reported that α,β-unsaturated moiety displayed acetylcholine esterase (AChE) and butylcholine esterase (BuChE) inhibition and may serve as promising agent in the treatment of alzeihmer's disease (Bag et al., 2013; Silva et al., 2013; Bukhari et al., 2014b). In addition, the ketone functional group of these compounds is believed to possess anticancer potential (Sahu et al., 2012; Bukhari et al., 2014c; Qin et al., 2016).

Recently, Rodrigues et al. (2016) suggested that compounds containing α,β-unsaturated carbonyls may not serve as good leads for drug design because of their potential to undergo Michael addition reaction leading to unwanted side effects, such as cytotoxicity and cell-damage. However, direct interaction of the groups with enzymes can be desirable. For example these compounds with Michael-accepting features can block carcinogenesis by inducing certain enzymes such as glutathione S-transferase and quinone reductase activity, which inhibits the reactive electrophilic forms of carcinogens. α,β-Unsaturated carbonyls may also be desirable moieties as they also have the ability to be radical scavengers through covalent ligand binding to target proteins or act as antioxidants, for example by thiol trapping.

Immunosuppression of natural α,β-unsaturated carbonyl-based compounds on the innate immune system

Curcumin and its analogs have been shown to be able to arrest lymphocytes and antigen presenting cells (APC) in autoimmune diseases (Bright, 2007). As evident in arthritis, they seemed to inhibit neutrophil activation and subsequent reactive oxygen species (ROS) production along with suppression of nuclear factor kappa B (NF-κB) and other inflammatory cytokines released by white blood cells (Jackson et al., 2006; Jančinová et al., 2009). In a similar manner, curcumin exerted antioxidant effect, reducing hyperglycemia and also inhibited macrophages-mediated tumor necrosis factor (TNF) and interleukin-6 (IL-6) release, activated by dying or stressed B cells (Raine, 1990; Maradana et al., 2013). Moreover, it was identified that the increased number of CD8+ T cells has been reduced by the use of curcumin (Aggarwal and Harikumar, 2009). Correspondingly, chalcone and its derivatives have been recognized as exhibiting therapeutic potential in immune diseases by targeting NF-κB signaling pathway, kinase activities and others assumed to be involved in cancer, diabetes, inflammatory diseases, and certain infections (Zhou and Xing, 2015). Zerumbone found to possess significant effects on immune system through controlling the regulation of cytokines and chemokines secretion in immune cells (Keong et al., 2010; Shieh et al., 2015). Table 1 summarizes the effects of α,β unsaturated carbonyl-based compounds on immune cells. The chemical structures of natural α,β-unsaturated carbonyl-based compounds, and their analogs and derivatives which exhibited strong immunomodulatory effects on granulocytes (compounds 4–32), monocytes, and macrophages (compounds 33–71), and dendritic cells (compounds 72–74) are shown in Figures 35, respectively.

Table 1.

Effects of α,β unsaturated carbonyl-based compounds on immune cells.

Type of cells α,β-unsaturated carbonyl based compounds Model used Key effects References
CURCUMIN AND CURCUMIN ANALOGS
Neutrophils Curcumin Monkey ↓Production of ROS Srivastava, 1989
Curcumin Murine ↓Raised level of PKC enzymes Jančinová et al., 2009
Curcumin Chondrocyte ↓Inflammatory process Jackson et al., 2006
Curcumin Human ↓Chemotaxis ↓IL 8 induced signal transduction pathway Takahashi et al., 2007
Curcumin Human ↓Cytokine induced neutrophil chemo attractant Lian et al., 2006
Diarylpentanoid analogs Human ↓ROS production Bukhari et al., 2015
Pyranopyridine,pyrazole pyridines and pyridopyrimidines Human ↓ROS production Al-Omar et al., 2005
Synthetic curcumin analog Human ↓ROS production Youssef et al., 2004
Eosinophils Curcumin Murine ↓Migration and IL-4 and IL-5 synthesis Moon et al., 2008
Mast cells Curcumin Murine ↓TNF-αand IL-4 ↓Histamine release Lee et al., 2008; Kurup and Barrios, 2008
Monocytes /macrophages Curcumin Human ↓Adhesion to human endothelial cells Kumar et al., 1998
Curcumin Human ↓TNF-α, IL-8, MiP-1α, MCP-1, IL-1β Abe et al., 1999
Curcumin U937 cells ↓MCP-I Lim and Kwon, 2010
Curcumin Murine ↓NO, TNF-α, IL-8 Bisht et al., 2009
Curcumin Murine ↓TLR4 mRNA expression Matsuguchi et al., 2000
Curcumin U937 cells ↓Oxidative stress, IL-8, TNFα, IL-6 Jain et al., 2009
Curcumin ↓Amyloid β-deposition Hamaguchi et al., 2010
Curcumin THP-1 ↓TNF-α,IL-1β,MCP-1,IL-8,MIP-1β, CCR5 Giri et al., 2004
Curcumin THP-1 ↓Th1 cytokine response, ↓NO production Bhaumik et al., 2000
Curcumin Human ↓Release of TNF and IL-1 Chan, 1995
Dibenzoyl methane, Tetrahydrocurcumin and Trimethoxydibenzoylmethane Murine ↓COX-2 expression, ↓5-LOX activity ↓PLA2 phosphorylation Hong et al., 2004
Bis dimethoxy curcumin Murine ↓NO production Kim et al., 2010
Diacetyl curcumin manganese complex ↓NO production Sumanont et al., 2004
Hexahydrocurcumin Murine ↓PGE2 synthesis, ↓iNOS Lee et al., 2005
Unsymmetrical monocarbonyl curcumin analogs Human and Murine ↓PGE2 synthesis Aluwi et al., 2016
Demethoxycurcumin Murine ↓NO production, ↓iNOS Pae et al., 2008
Diarylpentanoid analogs of curcumin Murine ↓NO production Lee et al., 2009
Diarylpentene dione curcumin series Murine ↓NO production Leong et al., 2014
2 benzoyl-6-benzylidene cyclohexanone curcumin series Murine ↓NO production Leong et al., 2015
1,5 diphenylpenta-2,4-dien-1-one Murine ↓TNF-α and IL-6 Liang et al., 2009a
Monocarbonyl curcumin analogs Murine ↓TNF, IL-1, IL-6,MCP-1,COX-2,PGE2,iNOS Liang et al., 2009b
Asymmetric monocarbonyl analogs Murine ↓TNF- α, IL-6 Zhao et al., 2015
Curcumin analogs Murine ↓TNF- α, IL-6 Zhang et al., 2015
Symmetric and asymmetric monocarbonyl curcumin analogs Murine ↓TNF- α, IL-6 Zhang et al., 2014
Dendritic cells Curcumin Human ↓Proliferation of helper T-cells Shirley et al., 2008
Curcumin Murine ↓Activities of regulating T-cells, ↓Oversuppression of CD 86, CD80, MHC II Kim et al., 2005
Curcumin Murine ↓Of indoleamine 2,3 dioxygenase Platt et al., 2010
Curcumin Murine ↓IDO production and T-cell proliferation Jeong et al., 2009
Curcumin Murine ↓IL-12/23p40 Larmonier et al., 2008
T cells Curcumin Murine ↓Release of IL-2 and IFN-γ Gao et al., 2004
Curcumin Jurkat ↓Proliferation of rat thymocytes Sikora et al., 1997
Curcumin Human ↓Quiescent T-cells Magalska et al., 2006
Curcumin Murine ↓OKT3 monoclonal antibody Sikora et al., 2006
Curcumin Human ↓Proliferation Deters et al., 2008
Curcumin Murine ↓Proliferation, ↓IL-2 and IFN-g Gao et al., 2004
Curcumin Murine ↓IL-17 level,IL-17 mRNA expression Xie et al., 2009
Curcumin Murine ↓TLR4 and TLR9 receptor expression Chearwae and Bright, 2008
Curcumin Murine ↓IL-12 production Natarajan and Bright, 2002
Curcumin Human ↓Lymphocyte proliferation Moon et al., 2010
B cells Curcumin ↓Proliferation and induce apoptosis Han et al., 1999
Curcumin Murine ↓Proliferation Decoté-Ricardo et al., 2009
Curcumin Murine ↓Proliferation and release of IgG1 and IgG2 Sharma et al., 2007
Curcumin Murine ↓Release of IgE antibodies Kuramoto et al., 1996
Curcumin Human ↓B-cell immortalization Ranjan et al., 1998
Curcumin Human ↑Apoptosis Ranjan et al., 1999
Natural killer cells Curcumin Murine ↓LAK cell production Gao et al., 2004
Curcumin Human ↓Release of IFN-γ and granzyme B Bill et al., 2009
Curcumin TS/A cell line ↓Function and activity Zhang et al., 2007
Curcumin Murine ↓Proliferation Yadav et al., 2005
Curcumin ↓Proliferation Kim et al., 2005
ZERUMBONE AND ITS DERIVATIVES
Neutrophils Zerumbone Murine Blocking infiltration of PMNs Chen et al., 2011
Eosinophils Zerumbone Murine Prevent eosinophilic pulmonary infiltration Shieh et al., 2015
Monocytes /macrophages Zerumbone Murine ↓COX-2 expression Murakami et al., 2005
Zerumboneoxide Murine ↓NO production Jang et al., 2005
Zerumbone Murine ↓NO production Syahida et al., 2006
Zerumbone THP1 cells ↓AP-1 and NF-κB Eguchi et al., 2007
Zerumbone Murine ↓PGE2 and NO production Chien et al., 2008
Zerumbone Mouse monocytes and human breast tumor cells ↓RANKL-induced NF-κB activation, ↓IκBα kinase Sung et al., 2009
Zerumbone Murine ↓COX-2 and iNOS Ohnishi et al., 2009
zerumbone and zerumbone 2,3-epoxide Murine ↓NF-κB activation ↓NO production Giang et al., 2009
Zerumbone U937 cells U937 macrophages protection from TCDD and DDT mediated the toxic actions Sciullo et al., 2010
Zerumbone Murine ↓mRNA, iNOS and IL-1β. Igarashi et al., 2016
Dendritic cells Zerumbone Murine ↓Antigen presenting cells (type A) Ganabadi and Kadir, 2009
Zerumbone Murine ↓Production of eotaxin, KC, IL-4, IL-5, IL-10, and IL-13 Shieh et al., 2015
T cells Zerumbone ↑Apoptosis Abdelwahab et al., 2011
Zerumbone Jurkat ↓T- cells proliferation ↑apoptosis Rahman et al., 2014
CHALCONE AND CHALCONE DERIVATIVES
Neutrophils 2-methoxy-4,4′ dihydroxy-5- α, α-dimethyl ally chalcone Human Biosynthesis of LTB4 and LTC 4 Kimura et al., 1988
2-methoxy-3,4,4′ trihydroxychalcone Human Biosynthesis of LTB4 and LTC 4 Kimura et al., 1988
Viscolin Human ↓Free radical production and elastase secretion Hwang et al., 2006
Brousso chalcone A Human ↓Respiratory burst Wang et al., 1997
2′,5′ dihydroxy-2-naphthyl chalcone Neutrophil degranulation Hsieh et al., 1998
(E) -1-[2-hydroxy-4-methoxy-3-(morpholine-methyl)phenyl]-3-(pyridine-2-yl)prop-zen-1-one Human ↓Production of superoxide ion and elastase release Reddy et al., 2011
(E) -1-[4-ethoxy-2-hydroxy-5-(-(morpholine-methyl)phenyl]-3-(pyridine-2-yl)prop-zen-1-one Human ↓Production of superoxide ion and elastase release Reddy et al., 2011
Phenyl sulfonyl uranyl Murine ↓Chemotaxis, ↓MPO, ↓ROS, ↓Elastase, ↓LTB4 production, ↓elastase, superoxide anion and LTB4 Araico et al., 2006
1-(2,3,4 trimethoxyphenyl)-3-(3-2-chloroquinolinyl)-2-propen-1-one Human and Murine ↓Elastase, superoxide anion and LTB4 De Leon et al., 2003
Bratelactone Human ↓Elastase release and superoxide synthesis Wu et al., 2013
2′,5′ dihydroxy-2-furfuryl chalcone Murine ↓Respiratory burst Wang et al., 2003
Basophils Chalcone Human ↓Histamine release Middleton and Drzewiecki, 1984
Liccochalcone RBL-2H3 cells ↓Activation of ERK pathway Tanifuji et al., 2010
4′-o-B-D-glucopyronosyl-4-hydroxy-3′-methoxy chalcone Human ↓Release of intra granular mediator Middleton and Drzewiecki, 1984
4′-o-B-D-glucopyronosyl-4-hydroxy-3′-dimethoxy chalcone Human ↓Release of intra granular mediator Middleton and Drzewiecki, 1984
Monocytes /macrophages 2′,4′,6′tris(methoxy methoxy)chalcone Murine ↓NO production, ↓iNOS Lee et al., 2006
2,4,6 trimethoxy acetophenone Murine ↓NO production Chiaradia et al., 2008
Trans -1,3-diphenyl-2,3-epoxypropane-1-one Murine ↓NO and PGE2 production Kim et al., 2013
3-phenyl-1-(2,4,6-tris(dimethoxy)phenyl)prop-2-yn-1-one Murine ↓AP-1 and ↓NO, ↓TNF- α Park et al., 2009
4-dimethylamino-3′,4′ dimethoxy chalcone Mice ↓iNOS expression Herencia et al., 2001
2′,4-dihydroxy-6′-isopentlyoxy chalcone Murine ↓TLP4 mediated NFK-β activation Roh et al., 2011
Sofalcone Murine ↓TNF-α, MCP-1, NO Tanaka et al., 2009
Naringenin Murine ↓TNF-α, MCP-1, NO Hirai et al., 2007
Okanin Murine ↓iNOS and NO Kil et al., 2011
Phenyl Sulfonyl Uranyl chalcone Murine ↓PGE2 Araico et al., 2006
Dendritic Cells Licochalcone A Human ↓Release of IL-6 and TNF-α Kolbe et al., 2006
Xanthohumol Murine ↑Apoptosis Xuan et al., 2010
T cells Chalcone Murine ↓Production and function of CD8+ cells Schwartz and Middleton, 1984
Xanthohumol Murine ↓Proliferation of CD8+ T-cells and ↓Release of IL-2,IFN-γ and TNF-α Gao et al., 2009
Dendritic cells Zerumbone Murine ↓Antigen presenting cells (type A) Ganabadi and Kadir, 2009
Licochalcone A Human ↓Proliferation and release of IFN-γ Barfod et al., 2002
Naringenin Murine ↓Release of Th-2 cytokines Iwamura et al., 2010
Naringenin Murine ↑T-cell apoptosis, ↓mRNA expression of IL-2, IFN-γ and TNF-α Fang et al., 2010

*↑, Enhanced/Upregulation; ↓, Decreased/Inhibited/Downregulation.

Figure 3.

Figure 3

Chemical structures of α,β-unsaturated carbonyl-based compounds with strong immunosuppressive effects on granulocytes.

Immunosuppressive effects of curcumin on granulocytes

Numerous lines of evidence suggest that curcumin may abate the neutrophil mediated inflammatory responses by varying different aspects of neutrophil function. Curcumin treatment inhibited zymosan and n-formyl-methionine-leucyl-phenylalanine (fMLP)-activated monkey neutrophils. It also suppressed the production of oxygen free radicals induced by arachidonic acid (Srivastava, 1989). The reduced production of oxygen free radicals by curcumin treatment may play an important role in rheumatoid arthritis. Jančinová et al. (2009) reported that curcumin inhibited the raised level of protein kinase C (PKC) isozymes by neutrophils in adjuvant induced arthritis. In the same way, curcumin inhibited the inflammatory processes initiated by crystal-induced neutrophil activation in a rheumatoid arthritis model (Jackson et al., 2006). The inhibition of transmigration and recruitment of neutrophils from blood vessels to the underlying liver tissue by curcumin has also been investigated in septic shock. The authors correlated the reduction of neutrophil's infiltration to the blocked expression of intercellular adhesion molecule 1(ICAM-1) and vascular cell adhesion protein 1 (VCAM-1) in the liver tissue with curcumin treatment (Madan and Ghosh, 2003). In another study, curcumin mediated inhibition of neutrophil's chemotaxis in a dose-dependent manner. It was reported that curcumin successfully impeded IL-8 (strong neutrophil chemoattractant) produced by monocytes and macrophage and also blocked IL-8 induced signal transduction pathway in neutrophils (Takahashi et al., 2007). Curcumin also reduced the level of cytokine-induced neutrophil chemoattractant (CINC) in acute lung injury. Based on the results, it was evidenced that curcumin exhibited anti-inflammatory activity by dampening CINC protein levels, which is similar in properties to human cytokine IL-8 and by diminishing the myeloperoxidase activity, a marker for damage and deterioration in lung tissues (Lian et al., 2006).

A study on the effect of curcumin on eosinophils in a murine model of asthma has shown that it inhibited the ovalbumin-(OVA) induced airway inflammation by three different mechanisms i.e., by suppressing the expression of inducible nitric oxide synthase (iNOS) and NO (nitric oxide) production responsible for significant lung tissue detriment; by hampering the recruitment of eosinophils and inflammatory cells that leads to the inflammation of airways; and by repressing the levels of IL-4 and IL-5 in broncho alveolar lavage fluid (Moon et al., 2008). In a model of cutaneous anaphylaxis, the antiallergic activity of curcumin was determined in vivo. The authors concluded that curcumin not only blocked the antigen-mediated activation of mast cells but also inhibited the secretion of cytokines like TNF-α and IL-4 by the mast cells, the underlying pathophysiology of atopic allergic reactions (Lee et al., 2008). In addition, another study indicated that curcumin inhibited the release of histamine from the mast cells, exhibiting anti-allergic effects in a murine model of allergy (Kurup and Barrios, 2008). During myocardial ischemia/reperfusion injury, it was shown that curcumin significantly lessen the myeloperoxidase activity, an index of neutrophils infiltration, hence alleviating cardiomyocytic apoptosis and global ischemia (Yeh et al., 2005).

A new series of curcumin analogs with α,β-unsaturated moiety i.e., pyrano pyridines, pyrazole pyridines, and pyrido pyrimidines has also revealed the antioxidant potential against free radical scavenging activity in isolated peripheral multinuclear neutrophils cells (PMNs) from the blood of healthy donors. Among the compounds tested, compound 4 exhibited the highest antioxidant activity (Al-Omar et al., 2005). Bukhari et al. (2015) assessed the inhibitory abilities of 17 diarylpentanoid analogs of curcumin against ROS production. The chemiluminescence assay was performed by using isolated PMNs and it was reported that compounds 5 and 6 showed strong inhibition on intracellular and extracellular ROS production by neutrophils with IC50 values ranging from 4.2 to 6.2 uM. In another study, a synthetic curcumin analog (7) exhibited a strong antioxidant activity by inhibiting neutrophils-mediated free radical scavenging activity against diphenylpicrylhydrazyl free radical test (DPPH; Youssef et al., 2004). Investigation on the immunomodulatory effects of 43 curcumin diarylpentanoid analogs revealed that compounds 8, 10, 13, and 14 were found to possess marked inhibitory effect on the oxidative burst of PMNs as well as compounds 9, 10, 11, 12, and 15 which exhibited potent inhibition of migration of PMNs (Jantan et al., 2012).

Immunosuppressive effects of chalcone and its derivatives on granulocytes

Chalcone derivatives have also been found to play an important role on neutrophil's activities and functions. Kimura et al. (1988) reported that two chalcones i.e., 2-methoxy-4,4′-dihyroxy-5-α,α-dimethyl-allyl chalcone (16) and 2-methoxy-3,4,4′-trihydroxychalcone (17) isolated from Glycyrrhiza glabra inhibited the biosynthesis of leukotrienes, LTB4 and LTC4 in human neutrophils. The synthesis of leukotrienes was stimulated by calcium-ionophore and was considered to be involved in the pathology of various diseases. Broussochalcone A (18), found in Broussonetia papyrifera, has showed a dose-dependent inhibition of fMLP and PMA elicited respiratory burst in activated rat neutrophils. Inhibition of PKC activity and suppression of NADPH oxidase activity were among the different contributing factors exhibiting the aforementioned effects (Wang et al., 1997).

Hsieh et al. (1998) reported the anti-inflammatory effects of a newly synthesized 2′,5′-dihydroxy-2-naphthylchalcone (19) which blocked fMPL-activated rat neutrophils which further blocked the release of β-glucuronidase and lysozyme. Human neutrophils mediated anti-inflammatory responses by viscolin (20), a chalcone isolated from Viscum coloratum has been reported. It was observed that viscolin suppressed the free radicals production and elastase release by the fMLP stimulated human neutrophils and these effects were found to be associated with an enhanced levels of cellular cyclic adenosine monophosphate (cAMP) through the inhibition of cAMP-specific phosphodiesterase (PDE) degradative enzymes (Hwang et al., 2006). In another study, Mannich bases of heterocyclic chalcones i.e., (E)-1-[2-hydroxy-4-methoxy-3-(morpholinomethyl)phenyl]-3-(pyridin-2-yl)prop-2-en-1-one (21) and (E)-1-[4-Ethoxy-2-hydroxy-5-(morpholinomethyl)phenyl]-3-(pyridin-2-yl)prop-2-en-1-one (22) exhibited similar inhibitory effects (production of superoxide anion and elastases) in human neutrophils (Reddy et al., 2011).

Another chalcone derivative, phenylsulfonyl uranyl has been reported to reduce the chemotaxis process during inflammatory conditions. Also it seemed to be suppressing myeloperoxidase generation along with the production of elastases and oxygen free radicals in neutrophils stimulated by different inducers including PMA, fMLP, and cytochalasin B. These effects are correlated with the inhibition of LTB4, an important leukotriene synthesized by the enzyme 5 lipoxygenase during the lipoxygenase pathway (Araico et al., 2006). Furthermore, De Leon et al. (2003) also studied the aforementioned parameters with the synthetic chalcone derivative, 1-(2,3,4-trimethoxyphenyl)-3-(3-(2-chloroquinolinyl)-2-propen-1-one (23) and documented its inhibitory function on neutrophils. The anti-inflammatory effects through the inhibition of CD11b expression, elastase release and free radicals generation in fMLP activated neutrophils have been exhibited by a novel chalcone, bratelactone, (24) isolated from Fissistigma bracteolatum. The observed underlying mechanism involved the blockage of calcium signaling, particularly store operated calcium entry block (SOCE) which is considered of paramount importance in activation of human neutrophils (Wu et al., 2013). Phospholipid D, an important component involved in the synthesis of phosphatidic acid, required for the activation of NADPH oxidase which is further important for neutrophil activation. Therefore, the inhibition of phospholipase D activation, by blocking PKC, Rho A, and ADP-ribosylation factor (ARF) membrane association is one of the critical mechanism in suppressing neutrophil's function. Another chalcone derivative, namely, 2′, 5′-dihydroxy-2-furfurylchalcone (DHFC) (25) has manifested dose-dependent inhibition of oxidative burst in fMLP activated neutrophils employing same mechanism as stated earlier (Wang et al., 2003).

Middleton and Drzewiecki (1984) revealed the inhibitory effects of chalcones on the release of histamine, an important cell derived inflammatory mediator, by human basophil. The authors studied the effect of different inducers antigen, anti-IgE, concanavalin (CON-A), ionophore, fMLP, and tetrade-canoylphorbol acetate to stimulate basophil cells. Likewise, Itoh et al. (2010) reported the anti-allergic role of two chalcone derivatives i.e., 4′-O-β-D-glucopyranosyl-4-hydroxy-3′-methoxychalcone (26) and 4′-O-β-D-glucopyranosyl-3′,4′-dimethoxychalcone (27) isolated from Brassica rapa L. using rat RBL-2H3 basophilic cells. The results revealed that chalcones inhibited the release of intra granular mediators in response to an antigen stimulus. Another study demonstrated the same inhibitory effects in rat RBL-2H3 basophilic cells by a chalcone derivative namely; licochalcone D (28) isolated from the root Xinjiang liquorice. These antiallergic effects accounted for their capability to inhibit the activation of the extracellular signal regulated kinase pathway (ERK) and extracellular Ca2+ influx (Tanifuji et al., 2010).

Immunosuppressive effects of zerumbone on granulocytes

Chen et al. (2011) demonstrated the effect of zerumbone on ultraviolet B (UVB)-induced corneal damages in female imprinting control region (ICR) mice where infiltration of PMNs was significantly blocked by the treatment of dietary zerumbone. The UVB-induced corneas were found to contain infiltrative PMN leukocytes in stroma and aqueous humor. Few PMN leukocytes were shown to attach with endothelial layer possessing a significant risk of attack to endothelial cells of cornea. Zerumbone was found to ameliorate UVB-treated corneal damages. It has been evidenced that infiltration of PMN leukocytes was suppressed with dietary zerumbone in a concentration-dependent manner. Recently, Shieh et al. (2015) reported that zerumbone has the ability to prevent eosinophilic pulmonary infiltration. Treatment with zerumbone inhibited the airway inflammation followed by reducing eotaxin production in murine model of asthma. Eotaxin is a most significant chemokine for recruiting eosinophils. Investigating this chemokine level in bronchoalveolar lavage fluid (BALF) revealed that treatment with zerumbone remarkably inhibited the eotaxin secretion. This inhibition of eotaxin level thought to be due to the direct or indirect influence exhibited on recruiting eosinophils. Furthermore, the less infiltration and activation of eosinophils in the lung of zerumbone-induced mice thought to have revealed in inhibited IL-5 expression in BALF as eosinophils are also considered for the source of IL-5.

Immunosuppressive effects of curcumin on monocytes and macrophages

The inflammatory responses mediated by monocytes and macrophages play a pivotal role in chronic inflammatory conditions. Kumar et al. (1998) reported that curcumin exhibited anti-inflammatory effects by blocking the adhesion of monocytes on human endothelial cells. These effects have been attributed to the inhibition of NF-κB which is responsible for the expression of proteins like ICAM-1, VCAM-1, and endothelial cell leukocyte adhesion molecule-1 (ELAM-1) on monocytes, induced by TNF. Also it has shown concentration-dependent inhibition of certain inflammatory cytokines secretion i.e., TNF-α, IL-8, macrophage inflammatory protein 1 alpha (MIP-1α), monocyte chemoattractant protein (MCP-1) and IL-1β after monocytes and macrophages had been stimulated by PMA or lipopolysaccharide (LPS; Abe et al., 1999). Lim and Kwon (2010) also revealed similar findings in their study that curcumin suppressed the expression of MCP-1 in PMA-induced U937.

Monocytic cell lineage. MCP-1 is a key factor in macrophages migration toward the site of infection and this inhibition has been subjected to the blocking of ERK /and NF-κB transcriptional activity. Another study was conducted to determine the anti-inflammatory role of curcumin by assessing different functions of macrophages viz NO production, phagocytosis and cytokines release. It was recognized that this multi targeting agent inhibited the synthesis of NO along with the blocking of TNF-α and IL-8 secretion by raw macrophages triggered by LPS. On the other hand, it enhanced the phagocytic activity and CD14 surface expression which was suggested as an indirect role of curcumin with unknown mechanism (Bisht et al., 2009).

Matsuguchi et al. (2000) observed the effects of curcumin on expression of toll like receptors in mouse macrophages in response to intraperitoneal injection of LPS. The results showed that pretreatment with curcumin significantly suppressed TLR4 mRNA expression which was subjected to NF-κB inhibition, suggesting that NF-κB is essential for this process. In diabetic condition, a massive increase in the inflammatory cytokines has been reported. In a model of streptozotocin-induced diabetic rats, the anti-inflammatory effect of curcumin was evaluated on the secretion of various inflammatory cytokines and also these effects were studied by using human promonocytic U937 cell line. Treatment with curcumin not only reduced enhanced levels of IL-8, TNF-α, IL-6, MCP-1 secreted as a result of increased glucose levels but also reduced cellular oxidative stress (Jain et al., 2009). Alzheimer's disease is a disorder presented mainly with massive amyloid-β (Aβ) peptide and monocytes and macrophages accumulation in the affected tissue. Increased levels of cytokines, TNF-α, and IL-1β and chemokines MCP-1, IL-8, and MIP-1β have also been observed. The ability of curcumin to modulate β-secretase and AChE activities led to decreased amyloid-β deposition and macrophages accumulation (Hamaguchi et al., 2010). Correspondingly, Giri et al., 2004) also explained the anti-inflammatory role of curcumin in Alzheimer's disease. It was reported that curcumin inhibited amyloid-β peptide aggregation and Aβ-induced expression of TNF-α, IL-1β, MCP-1, IL-8, MIP-1β, and CCR5 in THP-1 monocytic cells. In a model of subcutaneously transplanted AK-5 tumors, curcumin led to the suppression of type 1 T helper (Th1) cells cytokine response and NO production by macrophages, suggesting that the host macrophages played an important modulatory role in the remission of AK-5 tumor (Bhaumik et al., 2000). Curcumin has also been found to hamper the release of TNF and IL-l as a result of inhibition of NF-κB by human monocytic macrophages triggered by LPS. This pleiotropic cytokines play a crucial role in different acute and chronic inflammatory diseases e.g., atherosclerosis, AIDS and autoimmune disorders (Chan, 1995). Likewise, Gao et al. (2004) also investigated the suppression of aforementioned cytokines in peritoneal macrophages by diferuloylmethane.

Immunosuppressive effects of curcumin analogs and derivatives on monocytes and macrophages

The reduced level of heme oxygenase-1 expression in RAW264.7 cells treated with bisdemethoxycurcumin (29) was found as one of the mechanisms of LPS-mediated NO production inhibition. Also this anti-inflammatory mechanism involved Ca2+/calmodulin- CaMKII-ERK1/2-Nrf2 cascade in RAW264.7 macrophages (Kim et al., 2010). Anti-inflammatory activity mediated by manganese complexes of curcumin (CpCpx) and diacetylcurcumin manganese complex (AcylCpCpx) exhibited enhanced NO radical scavenging activity as compared to their parent compounds, curcumin and acetylcurcumin, respectively (Sumanont et al., 2004). Skin wound healing involves androgen receptor signaling and these receptors have been found in different cell types including keratinocytes, dermal fibroblasts, and infiltrating macrophages. Lai et al. (2009) evaluated the curcumin derivative ASC-J9, against general and myeloid-specific AR knock out (ARKO) mice. The study concluded that the topical application of ASC-J9 cream in mice caused accelerated wound healing by inhibiting the androgen receptor activity and suppressed expression of local TNF-α expression. Anti-inflammatory activities mediated by naturally occurring curcumin and β-diketone derivatives namely dibenzoylmethane (30), triethoxydibenzoylmethane (31), tetrahydrocurcumin (32) using RAW 264.7 macrophages cell line have been investigated. The observed parameters included the release of AA and its metabolites (Hong et al., 2004). It was concluded from the results that curcumin and its analogs significantly affected the AA metabolism by blocking cytosolic phospholipase A2 (cPLA2) phosphorylation, suppressing cyclooxygenase 2 (COX-2) expression and decreasing the catalytic activities of 5 lipoxygenase (LOX) in LPS-stimulated raw macrophages.

Lee et al. (2005) evaluated newly synthesized α,β-unsaturated curcumin analogs i.e., diarylheptanoid analogs and diarylheptylamine analogs as COX-2 inhibitors. These compounds strongly inhibited COX-2 catalyzed biosynthesis in LPS-stimulated macrophages as a model system. Among all the compounds, hexahydrocurcumin (33) was the most potent one with an IC50 value of 0.7 μM. Also the authors reported that the above mentioned curcumin analogs could inhibit iNOS responses of LPS-stimulated macrophages exhibiting anti-inflammatory activities. A series of unsymmetrical monocarbonyl curcumin analogs were synthesized and their anti-inflammatory effects were determined. Human and murine macrophages stimulated by LPS to determine the effects on prostaglandin E2 (PGE2) production were used. The results suggested that compound 34 exhibited strong inhibition on the production of PGE2 in both cell lines (Aluwi et al., 2016). Another study investigated a more stable synthetic curcumin analog, dimethoxycurcumin (35), for NO production assay and compared with curcumin and bisdemethoxycurcumin (29). LPS activated macrophages were used to evaluate the inhibition of NO production and iNOS expression. The results showed that compound 35, curcumin and compound 29 inhibited NO production, iNOS expression with compound 35 being the most effective, followed by curcumin and compound 29, confirming that α,β-unsaturated carbonyl group is an important reactive structure of curcumin analogs. Additionally, this compound also revealed the inhibition of NF-κB in LPS-activated raw macrophages. Further mechanistic elucidation demonstrated that diminished NF-κB activation was achieved by blocking IκBα phosphorylation and IKK-α activity (Pae et al., 2008).

A newly synthesized series of curcumin related diarylpentanoid analogs have been shown to possess anti-inflammatory activity. Among the 46 compounds tested, three curcumin-like diarylpentanoid analogs which were 36, 37, and 38 showed remarkably high inhibitory effect upon NO production in RAW 264.7 cell line, as compared to positive control and curcumin. Inhibition of target protein was suggested as the mechanism responsible for the anti-inflammatory property of these compounds (Lee et al., 2009). Likewise, a series of 97 diarylpentanoid derivatives with diarylpentenedione series (halogenated, methoxylated, and polyphenolic) were synthesized and screened through NO suppression assay for their anti-inflammatory activity using interferon gamma (IFN-γ)/(LPS)-stimulated macrophages cells. However, compound 39 demonstrated the most significant NO suppression activity. The authors concluded their study by reporting that the diarylpentanoid structure with preserved ethylene and β-diketone moieties was a primary direction and should be investigated further toward finding new anti-inflammatory agents (Leong et al., 2014).

In another study, compound 40 belonging to 2-benzoyl-6-benzylidenecyclohexanone curcumin analogs series was evaluated for NO inhibition in LPS/IFN-induced RAW 264.7 macrophages model and was found to exhibit the highest activity with an IC50 value of 4.2 ± 0.2 μM (Leong et al., 2015). Analogously, in a model of IFN-γ/LPS-activated RAW 264.7 cells, similar results have been seen when a series of 1, 5-diphenylpenta-2, 4-dien-1-one analogs was evaluated for anti-inflammatory activity by measuring their NO inhibition activity (Faudzi et al., 2015). The most promising NO-inhibitory activity was displayed by compound 41, a 5-methylthiophenyl-bearing analog. As a sequence from previous study, the authors investigated the bioactivity of a newly synthesized compound 42 against LPS-induced TNF-α and IL-6 secretion by using mouse J774.1 macrophages (Liang et al., 2009a). Liang et al. (2009b) evaluated another 44 mono-carbonyl analogs for the inhibitory activities against LPS-induced TNF-α and IL-6 release in the macrophages. Among these compounds, three were selected to further evaluate the inhibitory effects on LPS-induced TNF-α, IL-1, IL-6, MCP-1, COX-2, PGES, iNOS, and p65 NF-κB mRNA production and it was observed that compound 43 exhibited significant inhibitory effects.

Newly synthesized 23 mono-carbonyl analogs of curcumin demonstrated anti-inflammatory activity in one study and among these, compounds 44 and 45 were recorded as the most potent analogs exhibiting anti-inflammatory activity in a dose-dependent manner. Their anti-inflammatory abilities were examined against TNF-α and IL-6 release in LPS-stimulated RAW 264.7 macrophages (Zhao et al., 2010). In another study, the author found that compound 46, a 2-nitro-substituted analog significantly (with the highest inhibition rate) suppressed the production of TNF-α and IL-6 in LPS-stimulated macrophages. Further investigation into the possible mechanism revealed that the anti-inflammatory activity of the analog might be associated with its inhibition against LPS-induced NF-κB and ERK pathway activation (Zhao et al., 2015). A very similar result was reported by evaluating the newly designed curcumin analogs for their anti-inflammatory effects in mouse peritoneal macrophages using ELISA kits. Active compound 47 exhibited highest inhibition on LPS-induced production of TNF-α and IL-6 and showed high chemical stability confirmed by UV absorption spectra (Zhang et al., 2015). In another study, the author classified the newly synthesized 34 monocarbonyl curcumin analogs into two series, symmetric monocarbonyl analogs of curcumin (SMAC) and asymmetric monocarbonyl analogs of curcumin (ASMAC). Among the analogs, the symmetrical heterocyclic type (compound 48 and 49) displayed the strongest inhibition against LPS-induced TNF-α and IL-6 release in mouse macrophages (Zhang et al., 2014).

Immunosuppressive effects of zerumbone and its derivatives on monocytes and macrophages

Zerumbone exhibited immunosuppressive effects on LPS-induced COX-2 expression in RAW264.7 murine macrophages followed by several mode of action (Murakami et al., 2005). Interestingly, a study reported that zerumbone derivatives, 5-hydroxyzerumbone and zerumboneoxide (50) suppressed LPS-induced NO production in RAW 264.7 cells with IC50 values of 14.1 and 23.5 μM, respectively (Jang et al., 2005) (Figure 4). In IFN-γ/LPS induced RAW 264.7 macrophages model, zerumbone also displayed more than 90% inhibition of NO production at the concentration of 50 μM (Syahida et al., 2006). Another study was carried out with differentiated Caco-2 cell lines to investigate the inhibitory effects of 16 selected food items on tissue plasminogen activator (TPA)-induced LOX-1 mRNA expression in THP-1 monocyte-like human cells and it was reported that zerumbone suppressed the transcriptional activities of activator protein (AP-1) and NF-κB (Eguchi et al., 2007). Zerumbone has also been documented as an inhibitor of PGE2 and NO production (Chien et al., 2008). Sung et al. (2009) found zerumbone to inhibit receptor activator for NF-kB ligand (RANKL) induced NF-κB activation in the mouse monocytes through the suppression of activation of IκBα kinase, IκBα degradation and IκBα phosphorylation as well as found to suppress osteoclast formation induced by human breast tumor cell lines.

Figure 4.

Figure 4

Chemical structures of α,β-unsaturated carbonyl-based compounds with strong immunosuppressive effects on monocytes and macrophages.

The inhibition of pro-inflammatory genes (COX-2 and iNOS) expression and enhanced detoxification genes gluthathione-S-transferases (GSTP1) and nicotinamide quinone oxidoreductase (NQO1) in RAW264.7 murine macrophages have been revealed by zerumbone (Ohnishi et al., 2009). In another comparative study, zerumbone and zerumbone 2,3-epoxide inhibited NF-κB activation and NO production in RAW 264.7 murine macrophages with respective IC50 values of 1.97 μM ± 0.18 and 30.11 μM ± 4.10 in activation of NF-κB assay and 3.58 μM ± 0.46 and 34.7 μM ± 3.72 in the NO production assay (Giang et al., 2009). Likewise, 5-hydroxyzerumbone found to suppress NO production in a dose-dependent manner with IC50 value of 19 μM (Min et al., 2009). In addition to RAW 264.7 macrophages, zerumbone has also been identified as a potential agent in protecting U937 macrophages from tetrachlorodibenzo-p-dioxin (TCDD) and dichlorodiphenyltrichloroethane (DDT)-mediated toxic actions (Sciullo et al., 2010). An intriguing study narrated the zerumbone-induced heat shock factor 1 (HSF-1) activation in stimulated macrophages for its anti-inflammatory functions. The outcomes revealed that zerumbone enhanced cellular protein aggregates and found to promote nuclear translocation of HSF-1 for heat shock protein (HSP) expression. Moreover, down-regulation of HSF1 attenuated the inhibitory effects of zerumbone on expressions of mRNA and proteins of pro-inflammatory genes, including iNOS and IL-1β (Igarashi et al., 2016).

Immunosuppressive effects of chalcone and its derivatives on monocytes and macrophages

Inhibition of NO synthesis by altering the expression of induced enzymes is one of the essential mechanisms to attain anti-inflammatory activity. Synthetic chalcones with α,β-unsaturated moiety, namely 2′,4′,6′-tris(methoxymethoxy) chalcone has also been reported to retard NO production by inhibiting iNOS expression along with the inhibition of NF-κB translocation into the nucleus in RAW 264.7 macrophages fostered by LPS (Lee et al., 2006). In a similar manner, 14 synthetic chalcones derived from 2,4,6-trimethoxyacetophenone revealed inhibitory action, in vitro, in relation to NO production in murine macrophages of the line RAW 264.7 induced by bacterial LPS (Chiaradia et al., 2008). Analogously, trans-1,3-diphenyl-2,3-epoxypropane-1-one (51), another chalcone derivative has disclosed the reduced production of NO and PGE2 in RAW 264.7 macrophages stimulated by LPS as a consequence of suppressed iNOS and COX-2 expression. Meanwhile, the reduced production of proinflammatory cytokines (TNF-α, IL-1β, and IL-6) has also been documented by compound 51 which was associated with the blocking of NF-κB activities as well as mitogen activated protein kinase (MAPK) phosphorylation. These two mechanisms seemed to be prominent in the pathophysiology of several inflammatory conditions (Kim et al., 2013).

The anti-inflammatory role of chalchone derivative i.e., 3-phenyl-1-(2,4,6-tris(methoxymethoxy)phenyl)prop-2-yn-1-one (52) was described by assessing the activity of AP-1 along with NO synthesis in murine RAW 264.7 macrophages (Park et al., 2009) The study revealed that the compound significantly suppressed the expression of certain AP-1 protein subunits induced by LPS and hence reduced the transcriptional activity of AP-1. The researchers also reported a dose-dependent abrogation of LPS-induced TNF-α secretion by a chalcone derivative (Franck et al., 2008). The inhibition of LPS stimulated NO and TNF-α production in RAW 264.7 macrophages by 2′-hydroxy-4′-methoxychalcone (53), 2′,4-dihydroxy-4′-methoxychalcone (54), and 2′,4-dihydroxy-6′-methoxychalcone (55) was attributed to the suppression of NF-κB and AP-1 activation that are considered indispensable for iNOS and cytokine gene expression (Figure 4; Ban et al., 2004).

Recently, a study also expressed that chalchone derivatives, (E)-1-[3-Hydroxy-4-(morpholinomethyl)phenyl]-3-(pyridin-4-yl)prop-2-en-1-one (56) and (E)-1-[3-Hydroxy-2,4-bis(morpholinomethyl)phenyl]-3-(pyridin-2-yl)prop-2-en-1-one (57) caused the prevention of NO synthesis in LPS- and IFN-γ-stimulated RAW 264.7 macrophages (Reddy et al., 2011). Besides, 4-dimethylamino-3′,4′-dimethoxychalcone (58) showed iNOS expression downregulation in cultured peritoneal macrophages extracted from mice (Herencia et al., 2001). On the other hand, a chalcone derivative, 2′,4-dihydroxy-6′-isopentyloxychalcone (JSH) (59) exhibited the inhibition of toll like receptors (TLR4)-mediated NF-κB activation in LPS-induced macrophages. These tolls like receptors (TLR-4) are usually manifested in macrophages and are imperative for eliciting innate immune responses (Roh et al., 2011). Tanaka et al. (2009) and Hirai et al. (2007) depicted that naringenin chalcone (60) and sofalcone (20-carboxymethoxy-4,40-bis(3-methyl-2-butenyloxy)chalcone) (61) showed their anti-inflammatory abilities by dose-dependent inhibition of LPS-induced TNF-α, MCP-1, and NO production in RAW 264.7 macrophages. The inhibitory effect of sofalcone on NO production was attributed to the activation of an enzyme (HO-1 expression) which plays a pivotal role in regulating the inflammatory condition (Tanaka et al., 2009).

Analogously, Kil et al. (2011) also reported, a naturally occurring chalchone, okanin (62), isolated from the genus Bidens and 3-penten-2-on inhibited LPS-induced iNOS expression and NO production in RAW264.7 macrophages through upregulation of HO-1 expression. Phenylsulfonyl uranyl chalcone derivative has been found to inhibit LPS-induced PGE2 production in RAW 264.7 macrophages in one study. These inhibitory effects of chalcone derivatives on the synthesis of PGE2 were correlated to the inhibition of COX-2 function selectively (Araico et al., 2006). The two chalcone derivatives 2′,5′-dimethoxy-4-hydroxychalcone (63) and 3,4-dichloro-2′,5′-diethoxychalcone (64) and another three synthetic chalcones 3,5-di-tert-butyl-2′,4,5′-trihydroxychalcone (65), 2′-hydroxy-3,4-dichlorochalcone (66), and 2′,5′-dimethoxy-4-hydroxychalcone (67) illustrated the retardation of NO synthesis in RAW 264.7 macrophages and microglial cells activated by LPS (Ko et al., 2003; Won et al., 2005).

Cardamonin, a chalcone derivative isolated from Artemisia absinthium L., and chemically known as 2′,4′-dihydroxy-6′-methoxychalcone (68), exerted anti-inflammatory effects in LPS -stimulated THP-1 monocytic cells/ IFN-γ activated RAW 264.7 macrophages. The inhibitory effects were seen on TNF-α production and iNOS protein expression which was subjected to restricted interaction of NF-κB to the DNA (Hatziieremia et al., 2006). 3-(2-hydroxyphenyl)-1-(5-methyl-furan-2- y-1)propenone (HMP) (69), revealed suppression of p38/ATF-2 and AP-1 signaling pathways, another mechanism, responsible for LPS mediated dose dependent inhibition of NO generation in RAW 264.7 macrophages (Liew et al., 2011). Two synthetic chalchones i.e., 3-(2,3-dimethoxy-phenyl)-1-naphthalene-1-yl-propenone (70) 4-(4-diethylamino-phenyl)-1,1-diphenyl-but-3-en-2-one (71) and two β-chlorovinyl chalcones have been documented to be able to suppress IL-6 and TNF-α release in LPS triggered RAW 264.7 macrophages and THP-1 cells (Bandgar and Gawande, 2010; Jantan et al., 2014).

Immunosuppressive effects of curcumin on dendritic cells

Dendritic cells (DCs) are of paramount importance in producing several immune responses and hence play fundamental role in different chronic pathological conditions. These cells have a pivotal role in initiating cell-mediated immunity and modification of dendritic cell's functions might be advantageous in eradicating immune disorders. A number of studies have investigated the immunomodulatory role of curcumin on dendritic cell's activities and functions. Curcumin owing to its immunosuppressive effects prevented the dendritic cells to respond to immune stimulants like LPS and proliferation of helper T cells. These inhibitory effects were subjected to suppression of maturation marker, cytokine and chemokine expression which further blocked the process of migration and endocytosis (Shirley et al., 2008). A study showed that curcumin could modulate dendritic cells mediated distinct immune responses in autoimmune disorders. It was reported that curcumin not only impeded the dendritic cell's maturation but also inhibited the subsequent stimulatory immune functions for regulating T cells activities. Also the over expression of CD86, CD80 and major histocompatibility complex II (MHCII) surface receptors were suppressed in LPS-stimulated dendritic cells after treatment with curcumin. It was observed that a dose of 50 μM proved to be lethal for DCs, reflecting the reactiveness of different immune cells to variable curcumin doses (Kim et al., 2005).

Indoleamine 2, 3-dioxygenase (IDO) is a heme containing immunomodulatory enzyme encoded by IDO1 gene and produced by several immunomodulatory cells like macrophages. On the other hand, IFN-γ, a cytokine, plays double role as an inducer and regulator of immune and inflammatory responses. It also regulates various responses of dendritic cells particularly, it shape up monocyte derived dendritic cells in cancer therapy and hence manage the polarizing activities of helper T cells 1. In one study, it was seen that IFN-γ enhanced IDO production in murine bone marrow derived DCs while curcumin displaying anti-inflammatory activity suppressed IDO production in above-mentioned cell line, further inhibiting IDO-mediated T cell proliferation. Modulation of janus kinase 1 (JAK) and PKC signaling pathway were recognized as mechanism for anti-inflammatory effects of curcumin in IFN-γ stimulated murine dendritic cells (Jeong et al., 2009).

In an in vitro model of the LPS-induced IL-12/23p40, difurolylmethane suppressed the production of IL-12/23p40 from the dendritic cells. The data from this study also suggested that curcumin depends on IL-10 to produce inhibitory immune responses and therefore by acting synergistically even at their suboptimal doses suppressed the LPS-induced IL-12/23p40 production from DCs (Larmonier et al., 2008). Curcumin has also been found to significantly inhibit release of LPS-stimulated inflammatory cytokines like IL-1B, IL-6, and TNF-α along with expression of IL-12 and dendritic cell's maturation which ultimately lead to poor cell -mediated immune responses and more likely to serve as a promising therapy in TH-1 mediated autoimmune disorders (Brouet and Ohshima, 1995).

Immunosuppressive effects of zerumbone on dendritic cells

In a study, the role of zerumbone was investigated on the infiltration of major histocompatibility complex (MHC) class II cells in collagen-treated osteoarthritis of rats. The outcomes revealed that zerumbone could inhibit APC (type A) followed by decreasing inflammatory process in osteoarthritis (Ganabadi and Kadir, 2009). Recently, another study documented the immunomodulatory effects of zerumbone on APCs (DCs) in vitro and its therapeutic role against OVA-induced T helper 2 (Th2)-mediated asthma in mouse model. The research group reported that LPS-activated bone marrow-derived dendritic cells along with zerumbone could enhance the proliferation of T cells and polarization of Th1 cell. In an animal model, oral administration of zerumbone produced lower OVA-specific IgE (IgE) and increment of IgG2a antibody production. Furthermore, treatment with zerumbone was found to decrease the production of eotaxin, keratinocyte-derived chemokine (KC), IL-4, IL-5, IL-10, and IL-13, and increase Th1 cytokine i.e., IFN-γ production in asthmatic mouse model (Shieh et al., 2015).

Immunosuppressive effects of chalcone and its derivatives on dendritic cells

Licochalcone A (72) blocked the secretion of IL-6 and TNF-α in LPS stimulated immature monocyte-derived human dendritic cells (Kolbe et al., 2006). In a detailed study, another chalcone, xanthohumol (73), exerted apoptotic activity in mice dendritic cells. This pharmacological effect has been recognized as a potential target to alleviate inflammation, as xanthohumol caused the activation of caspase 8 and caspase 3 which in turn led to DNA frag-mentation and destruction of intracellular proteins and hence caused apoptosis in dendritic cells (Xuan et al., 2010).

Immunosuppression of natural α,β-unsaturated carbonyl-based compounds on the adaptive immune system

Immunosuppressive effects of curcumin on T cells

Several studies have also documented the role of α,β-unsaturated compounds on lymphocytes. Curcumin inhibited the expression of inflammatory cytokines like IL-2 and IFN-Υ by T lymphocytes isolated from mouse spleen cells. Basically, the inhibition of transcription factor i.e., NF-κB by curcumin was one of the bottom line mechanism in suppressed cytokine release ultimately concluding that this multi-targeting agent mediated most of the immunosuppressive effects by obstructing NF-κB target genes (Gao et al., 2004). Similarly, another study reported that curcumin abrogated the proliferation of rat thymocytes stimulated by mitogen Con A in addition to inhibitory effects of curcumin on Con A triggered Jurkat T cell line. These antiproliferative effects of curcumin have been attributed to arrest AP-1 transcription factor activation (Sikora et al., 1997). However, in disagreement to the above mentioned study, it was also reported that curcumin could also cause cell death not only in proliferating human lymphocytes but also in normal non-dividing quiescent T cells via activation of caspase-3 protein. Although, proliferating T cells were more prone to damage as compared to quiescent T cells (Magalska et al., 2006; Sikora et al., 2006). Moreover, in another study the proliferation of T and B cells activated by OKT3 monoclonal antibody (a human TCR/CD3 complex Ab) was significantly blocked by curcumin (Deters et al., 2008). Curcumin also showed the notable inhibition of human T cells when these cells were stimulated by different inducers like PMA, CD28, phytohaemagglutinin (PHA; Ranjan et al., 1998).

Curcumin owing to its immunosuppressive effects inhibited the proliferation of helper T cells by preventing the dendritic cells to respond to immune stimulants like LPS. These inhibitory effects were subjected to suppression of maturation marker, cytokine, and chemokine expression which further blocked the process of migration and endocytosis (Shirley et al., 2008). Another study highlighted the effect of different doses of curcumin on Con A-stimulated proliferation of splenic cells in vitro. It was observed that at 6.25 μM concentration curcumin exhibited a significant decrease in proliferation while a complete blockage of proliferation was observed at 12.5 μM in splenic T cells. In addition, curcumin was found to suppress the release of IL-2 and IFN-Υ by splenic T lymphocytes as a result of inhibition of NF-κB target genes rather than affecting the levels of constitutively expressed NF-κB (Gao et al., 2004). One study documented the multiple roles of curcumin using T cells activated by different stimuli. The IL-12-induced STAT4 phosphorylation was found to be reduced by curcumin while the same effect was enhanced in response to IFN-β-induction. On the other hand, curcumin lowered IL-12 induced IFN-γ production and IL-12 Rβ1 and β2 expression, whereas it increased IFN-α-induced IL-10 and IFNAR1 expression (Fahey et al., 2007).

Interleukin 17 is a pro-inflammatory cytokine produced by T cells which further triggers T cells and other immune cells to produce a diversity of cytokines, chemokines, and cell adhesion molecule and plays a key role in the progression of encephalomyelitis. In an experimental model of encephalomyelitis, oral treatment of curcumin reduced IL-17 levels along with IL-17 mRNA expression, production of transforming growth factor beta (TGF-β) and also suppressed signal transducer and activator of transcription 3 (STAT-3) expressions and STAT3-phosphorylation. The blocked STAT3-phosphorylation in T cells also blocked the differentiation of Th-17 cells (Xie et al., 2009). In addition, the role of curcumin in the pathogenesis of multiple sclerosis has also been investigated. The results showed that curcumin inhibited the toll-like receptors 4 (TLR4) and toll like receptors 9 (TLR9) expression on CD4+ T and CD8+ T cells, immunized with PLPp139-151 and MOGp35-55 antigen. Mechanistically, it was found that these toll like receptors acted as co stimulatory receptors. Curcumin treatment led to the decrease in the expression of PLPp139-151 and MOGp35-55 Ag-induced TLR4 and TLR9 on the CD4+ T cells and CD8+ T cells, which also ameliorated this disease. It was found that TLR 4 and TLR9 acted as co-stimulatory receptors which further boost the cytokine production and proliferation in response to the specific agonists (Chearwae and Bright, 2008). Earlier, it was narrated that the inhibitory abilities of curcumin on IL-12 production in spleen T lymphocytes ameliorated experimental autoimmune encephalomyelitis (Natarajan and Bright, 2002). In a model of type II collagen induced arthritis (CIA), curcumin abrogated lymphocytes proliferation induced by bovine type II collagen Ag (Moon et al., 2010). And also found to inhibit PMA induced proliferation of T cells isolated from human spleen (Jagetia and Aggarwal, 2007). Curcumin exerted its immunosuppressive effects on T cells by tyrosine kinase, a CD28 co-stimulatory pathway of T-cell activation (Ranjan et al., 2004). Peripheral blood mononuclear cells (PBMCs) are largely comprised of T cells. Maier et al. documented that curcumin caused dose-dependent suppression of TH-1 type immune responses in mitogen stimulated PBMCs (Maier et al., 2010). Mechanistically, it was shown that this suppressive effect accounts to the inhibition of neopterin production mediated by IFN-γ along with the degradation of tryptophan.

Immunosuppressive effects of zerumbone on T cells

Abdelwahab et al. (2011) experimented the effects of zerumbone on T-acute lymphoblastic leukemia, CEM-ss cancer cells. Zerumbone was found cytotoxic to CEM-ss cells with an IC50 value of 8.4 ± 1.9 μg/mL. Additionally, zerumbone enhanced the number of TUNEL-positive stain and cellular level of caspase-3 on CEM-ss cells. Therefore, it's postulated that zerumbone has the ability to induce apoptosis on T-acute lymphoblastic leukemia, CEM-ss cells as well as it may help to cure leukemia. Similarly, another study was conducted to check the effect of zerumbone loaded into nanostructured lipid carriers (ZER-NLC) in human T-cell acute lymphoblastic leukemia (Jurkat) cells and concluded that ZER-NLC were able to possess antileukemic as a sustained-release drug carrier system for treating leukemia (Rahman et al., 2013). The author also reported the antiproliferative effect of zerumbone on T- cells (Jurkat) through apoptotic intrinsic pathway followed by activating caspase-3 and caspase-9 (Rahman et al., 2014).

Immunosuppressive effects of chalcones and derivatives on T cells

Chalcones with the reactive α,β-unsaturated carbonyl group have also been found to abrogate the production and function of normal cytotoxic (CD8) T cells in mouse spleen (Schwartz and Middleton, 1984). In contrast, another study documented that chalcone isoliquiritigenin (74) exhibited no effect on proliferation of lymphocytes induced by mitogen Con A and also mixed lymphocyte culture from mouse spleen (Namgoong et al., 1994). The chemical structure of compound 74 is shown in Figure 5. The antiproliferative effects of xanthohumol (73) as mentioned earlier were also investigated on T cells. It was reported that xanthohumol significantly inhibited the proliferation and development of cytotoxic T cells along with the release of cytokines from helper T cells (Th1) i.e., IL-2, IFN-γ, and TNF-α. These inhibitory effects were found to be associated with the depletion of IκBα phosphorylation in the NF-κB signaling pathway (Gao et al., 2009). In contrast, Choi et al. (2009) demonstrated that xanthohumol enhanced the release of cytokine IL-2 in a dose dependent fashion from PMA and ionomycin activated mouse EL-4 T cells. These elevated effects were attributed to the upregulation of nuclear factor of activated T cells and AP-1 in mouse EL-4 T cells.

Figure 5.

Figure 5

Chemical structures of α,β-unsaturated carbonyl-based compounds with strong immunosuppressive effects on dendritic cells.

Barfod et al. (2002) reported that the proliferation of T cells as well as release of IFN-γ from PHA-stimulated T cells has been dose dependently inhibited by licochalcone A, extracted from Chinese liquorice. Similarly another chalcone, naringenin (60) was investigated against helper T cells (CD4+) sensitized by OVA and it was observed that this chalcone notably reduced the secretion of Th2 cytokines i.e., IL-4, IL-5, and IL-13, from mice splenic CD4T cells (Iwamura et al., 2010). Naringenin, found in grapefruit and other citrus fruits, significantly abrogated picryl chloride (PCl)-induced contact hypersensitivity by suppressing the proliferation and activation of T lymphocytes. The mouse T cells were activated by anti-CD3 and anti-CD28. In addition, the aforementioned chalcone also inhibited the mRNA expressions of different cytokines, including IL-2, IFN-γ, and TNF-α. Simultaneously, naringenin also showed T cell apoptosis which was subjected to the upregulation of Bax, Bad, PARP (poly ADP ribose polymerase), cleaved-caspase 3 while downregulation of phosphorylated Akt, Bcl-2 was observed (Fang et al., 2010).

Immunosuppressive effects of curcumin on B cells

A study conducted by Han et al. (1999) showed that curcumin exerted antiproliferative effects in a dose-dependent manner on BKS-2, an immature B cell lymphoma. It was suggested that curcumin inhibited the proliferation and induced apoptosis of BKS-2 by inhibiting the activity of NF-κB and further suppressing the expression of survival and growth genes i.e., early growth response protein (egr-1), regulator gene that codes for transcription factor, (c-myc) Bcl-xL, tumor suppressor gene p53 (Han et al., 1999). Another study demonstrated that curcumin was a potent inhibitor of B cell activation and also associated signaling pathways. It was found that curcumin treatment demolished proliferation of B cells stimulated by toll-like receptor ligands LPS and CpG oligodeoxynucleotides. Furthermore, these inhibitory effects were accounted for the inhibition of phosphorylation of ERK, Iκ-B, and p38 kinase, NF-κB activation (Decoté-Ricardo et al., 2009). These observations indicated the anti-inflammatory effects of curcumin in the B cell response. Likewise, curcumin exerted immunosuppressive effects by inhibiting not only LPS induced proliferation of B cells in a dose-dependent manner but also LPS-induced secretion of IgG1 and IgG2 antibodies. The underlying mechanisms indicated were the downregulation of CD28 and CD80 expression along with up-regulation of CTLA-4 (Sharma et al., 2007). Correspondingly, the inhibitory effects of curcumin on production of IgE antibodies from rat splenocytes were also evaluated (Kuramoto et al., 1996).

Interestingly, in one study, curcumin has also been found to impede the B cell immortalization isolated from healthy human volunteers and stimulated by Epstein barr virus (EBV). This process of immortalization led to post-transplant lymphoproliferative disorders in patient usually on immunosuppressive drugs like cyclosporine A. However, the mechanism behind this effect was not explained (McDonald et al., 1998). Subsequently another study explained that curcumin regulated the B cell immortalization effect by causing an increased apoptosis in the B cells infected by EBV (Ranjan et al., 1999). Curcumin significantly elevated the production of IgG antibodies from B cells at a higher dose of 40 mg/kg as compared to lower doses (1, 20 mg/kg) where the antibody levels were found similar as that of control (South et al., 1997). Curcumin can also play a crucial role in the treatment of B cell autoimmune diseases. As evidence from one study, curcumin has shown concentration-dependent inhibition of activation-induced cytosine deaminase (AID) expression, an enzyme regulated by NF-κB and considered important for Ig class switch recombination and somatic hyper-mutation having a role in tumorigenesis. This effect was subjected to the demolished recovery of IgG+ class-switched B cells (Haque et al., 2010).

Immunosuppressive effects of curcumin on natural killer cells

A number of studies have investigated the role of α,β-unsaturated carbonyl-based compounds on natural killer cell activity against tumor cells. Earlier studies reported that administration of different doses of curcumin for duration of 5 weeks exhibited no effect on NK cell activity (South et al., 1997). Correspondingly, another study described that in vivo curcumin treatment for long duration exerted no effect on NK cell activity in ascites tumor development (Varalakshmi et al., 2008). In contrast, Yadav et al. (2005) demonstrated that treatment with curcumin enhanced the in vitro cytotoxicity of NK cells which could be supplemented by IFN-γ treatment. Lymphokine activated killer cells (LAK) are analogous to natural killer cells. Gao et al. (2004) evaluated the production of these non-specific LAK cells induced by IL-2 in addition to the determination of cytotoxic activity against YAC-1 lymphoma cells. The results concluded that higher doses of curcumin significantly reduced LAK cell production. It was also documented that curcumin treated natural killer cells, isolated from healthy donors, suppressed the release of IFN-γ and granzyme B in the presence of K562 and A375 melanoma cell lines (Bill et al., 2009). Recently, curcumin has also been found to increase the degradation of tumor derived exosomal proteins which ultimately inhibited the NK cell activity induced by IL2 against breast carcinoma. These effects of curcumin led to anti-tumor immune responses (Zhang et al., 2007). Another study displayed that curcumin exerted cytocidal effects by causing the cell death of NKL, NK-92, and HANKI (NK/T-cell lymphoma cell lines) which were not responding to other therapies. This anti-proliferative activity was subjected to the inhibition of NF-κB activation in addition to suppression of Bcl-xL, cyclin D1, XIAP, and c-FLIP expression and the subsequent cleavage and activation of caspase-8 and poly (ADP-ribose) polymerase (Yadav et al., 2005). Likewise, the inhibited proliferation of LAK cells was studied (Mandal and Viswanathan, 2015).

Immunosuppressive effects of chalcone and its derivatives on natural killer cells

Flavokawain A chalcone depicted in vivo antitumor activity in a dose-dependent manner and ultimately inhibiting NK cell activity in mice via interferon-a synthesis induction (Hornung et al., 1988). Wleklik et al. (1988) suggested that mice treated with amentoflavone or quercetin developed measurable serum content of interferon. The antitumor activity of naturally occurring flavonoids could be attributable to the immunomodulatory properties of induced interferons with associated augmentation of NK cell function (Verma et al., 1988). NK cell cytocidal activity against NK-sensitive K562 and U937 tumor target cells was accompanied by early increased incorporation of 32P into PI, suggesting activation of phospholipase C (Steele et al., 1990).

Conclusion and future prospects

α, β-Unsaturated carbonyl groups are widely distributed as reactive substructures of natural compounds and this has been exemplified by the natural products, curcumin, chalcone, and zerumbone. The immunosuppressive effects of these α,β-unsaturated carbonyl-based compounds and their analogs and derivatives have been comprehensively studied on neutrophils, monocytes, and macrophages. These compounds have also been investigated on other types of immune cells i.e., T cells, B cells, natural killer cells, and dendritic cells but far less as compared to neutrophils and macrophages. It is very important to further explore the biological reactivity of α, β-unsaturated carbonyl groups, especially on their effects on the immune cells in different pathological states. The inhibitory effects of the α, β-unsaturated carbonyl-based compounds on the immune cells play key role in inflammation. The anti-inflammatory activity of the compounds were partially mediated by their effects on the immune cells specifically on inhibition of pro-inflammatory cytokines expression, NO production, NF-κB activation, and iNOS. This review may provide useful information for other scientists to further examine more pharmacological effects of α, β-unsaturated carbonyl-compounds in different types of immune cells and hence come up with a promising agent that may serve as a lead compound for further development into potent immunomodulating agent in treating different immune related diseases particularly related to inflammatory disorders.

Author contributions

IJ and SNAB participated in the concept and editing of the manuscript and IJ gave the final approval of the final version to be submitted for publication. LA and MAH drafted the manuscript.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

This work was supported by the Dana Impak Perdana grant from Universiti Kebangsaan Malaysia (DIP-2015-013).

Glossary

Abbreviations

APC

antigen presenting cells

NF-κB

nuclear factor kappa B

TNFα

tumor necrosis factor alpha

ROS

reactive oxygen species

IL

interleukin

PBMCs

peripheral blood mononuclear cells

PMNCs

polymorphonuclear cells

fMLP

N-Formylmethionine-leucyl-phenylalanine

PKC

protein kinase C

ICAM-1

Intercellular Adhesion Molecule 1

VCAM-1

Vascular cell adhesion protein 1

CINC

cytokine induced neutrophil chemoattractant

OVA

ovalbumin

iNOS

inducible nitric oxide synthase

NO

nitric oxide

LTB4

leukotriene B4

PMA

phorbol 12-myristate 13-acetate

LPS

lipopolysaccharide

UVB

ultraviolet-B

BALF

bronchoalveolar lavage fluid

CON A

concanavalin A

ERK

extracellular signal-regulated kinases

MCP-1

Monocyte chemoattractant protein-1

MIP-1β

Macrophage Inflammatory Protein 1-beta

CCR5

chemokine receptor 5

AChE

acetylcholinesterase

PLA2

phospholipase A2

PGE2

prostaglandin E2

COX 2

cyclooxygenase 2

LOX

lipoxygenase

IFN-γ

interferon gamma

AP-1

activated protein 1

TLR

toll like receptors

DCs

dendritic cells

MHC

major histocompatibility complex

PHA

Phytohaemagglutinin

STAT

Signal transducer and activator of transcription 3

LAK

lymphokine activated killer cells.

References

  1. Abdelwahab S. I., Abdul A. B., Mohan S., Taha M. M., Syam S., Ibrahim M. Y., et al. (2011). Zerumbone induces apoptosis in T-acute lymphoblastic leukemia cells. Leuk. Res. 35, 268–271. 10.1016/j.leukres.2010.07.025 [DOI] [PubMed] [Google Scholar]
  2. Abe Y., Hashimoto S., Horie T. (1999). Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol. Res. 39, 41–47. 10.1006/phrs.1998.0404 [DOI] [PubMed] [Google Scholar]
  3. Aggarwal B. B., Harikumar K. B. (2009). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 41, 40–59. 10.1016/j.biocel.2008.06.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ahmad W., Kumolosasi E., Jantan I., Bukhari S. N., Jasamai M. (2014). Effects of novel diarylpentanoid analogues of curcumin on secretory phospholipase A2, cyclooxygenases, lipo-oxygenase, and microsomal prostaglandin e synthase-1. Chem. Biol. Drug Des. 83, 670–681. 10.1111/cbdd.12280 [DOI] [PubMed] [Google Scholar]
  5. Al-Omar M. A., Youssef K. M., El-Sherbeny M. A., Awadalla S. A., El-Subbagh H. I. (2005). Synthesis and in vitro antioxidant activity of some new fused pyridine analogs. Arch. Pharm. 338, 175–180. 10.1002/ardp.200400953 [DOI] [PubMed] [Google Scholar]
  6. Aluwi M. F. F. M., Rullah K., Yamin B. M., Leong S. W., Bahari M. N. A., Lim S. J., et al. (2016). Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E 2 production in LPS-induced murine and human macrophages cell lines. Bioorg. Med. Chem. Lett. 26, 2531–2538. 10.1016/j.bmcl.2016.03.092 [DOI] [PubMed] [Google Scholar]
  7. Anand P., Kunnumakkara A. B., Newman R. A., Aggarwal B. B. (2007). Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807–818. 10.1021/mp700113r [DOI] [PubMed] [Google Scholar]
  8. Anand P., Thomas S. G., Kunnumakkara A. B., Sundaram C., Harikumar K. B., Sung B., et al. (2008). Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem. Pharmacol. 76, 1590–1611. 10.1016/j.bcp.2008.08.008 [DOI] [PubMed] [Google Scholar]
  9. Araico A., Terencio M. C., Alcaraz M., Dominguez J., León C., Ferrandiz M. L. (2006). Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase. Life Sci. 78, 2911–2918. 10.1016/j.lfs.2005.11.017 [DOI] [PubMed] [Google Scholar]
  10. Bag S., Ghosh S., Tulsan R., Sood A., Zhou W., Schifone C., et al. (2013). Design, synthesis and biological activity of multifunctional α, β-unsaturated carbonyl scaffolds for Alzheimer's disease. Bioorg. Med. Chem. Lett. 23, 2614–2618. 10.1016/j.bmcl.2013.02.103 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ban H. S., Suzuki K., Lim S. S., Jung S. H., Lee S., Ji J., et al. (2004). Inhibition of lipopolysaccharide-induced expression of inducible nitric oxide synthase and tumor necrosis factor-α by 2′-hydroxychalcone derivatives in RAW 264.7 cells. Biochem. Pharmacol. 67, 1549–1557. 10.1016/j.bcp.2003.12.016 [DOI] [PubMed] [Google Scholar]
  12. Bandgar B. P., Gawande S. S. (2010). Synthesis and biological screening of a combinatorial library of β-chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents. Bioorg. Med. Chem. 18, 2060–2065. 10.1016/j.bmc.2009.12.077 [DOI] [PubMed] [Google Scholar]
  13. Barfod L., Kemp K., Hansen M., Kharazmi A. (2002). Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol. 2, 545–555. 10.1016/S1567-5769(01)00202-8 [DOI] [PubMed] [Google Scholar]
  14. Batovska D., Parushev S., Slavova A., Bankova V., Tsvetkova I., Ninova M., et al. (2007). Study on the substituents' effects of a series of synthetic chalcones against the yeast Candida albicans. Eur. J. Med. Chem. 42, 87–92. 10.1016/j.ejmech.2006.08.012 [DOI] [PubMed] [Google Scholar]
  15. Bhaumik S., Jyothi M. D., Khar A. (2000). Differential modulation of nitric oxide production by curcumin in host macrophages and NK cells. FEBS Lett. 483, 78–82. 10.1016/S0014-5793(00)02089-5 [DOI] [PubMed] [Google Scholar]
  16. Bill M. A., Bakan C., Benson D. M., Jr., Fuchs J., Young G., Lesinski G. B. (2009). Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol. Cancer Ther. 8, 2726–2735. 10.1158/1535-7163.MCT-09-0377 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Bisht K., Choi W. H., Park S. Y., Chung M. K., Koh W. S. (2009). Curcumin enhances non-inflammatory phagocytic activity of RAW264. 7 cells. Biochem. Biophys. Res. Commun. 379, 632–636. 10.1016/j.bbrc.2008.12.135 [DOI] [PubMed] [Google Scholar]
  18. Bright J. J. (2007). Curcumin and autoimmune disease. Adv. Exp. Med. Biol. 595, 425–451. 10.1007/978-0-387-46401-5_19 [DOI] [PubMed] [Google Scholar]
  19. Brouet I., Ohshima H. (1995). Curcumin, an anti-tumor promoter and anti-inflammatory agent, inhibits induction of nitric oxide synthase in activated macrophages. Biochem. Biophys. Res. Commun. 206, 533–540. 10.1006/bbrc.1995.1076 [DOI] [PubMed] [Google Scholar]
  20. Bukhari S. N. A., Jantan I., Jasamai M. (2013b). Anti-inflammatory trends of 1, 3-diphenyl-2-propen-1-one derivatives. Mini. Rev. Med. Chem. 13, 87–94. 10.2174/138955713804484767 [DOI] [PubMed] [Google Scholar]
  21. Bukhari S. N. A., Jantan I., Kumolosasi E., Jasamai M. (2015). Immunomodulatory effects of diarylpentanoid analogues of curcumin. Med. Chem. Res. 24, 3405–3411. 10.1007/s00044-015-1387-8 [DOI] [Google Scholar]
  22. Bukhari S. N. A., Jantan I., Masand V. H., Mahajan D. T., Sher M., Naeem-Ul-Hassan M., et al. (2014b). Synthesis of α, β-unsaturated carbonyl based compounds as acetylcholinesterase and butyrylcholinesterase inhibitors: characterization, molecular modeling, QSAR studies and effect against amyloid β-induced cytotoxicity. Eur. J. Med. Chem. 83, 355–365. 10.1016/j.ejmech.2014.06.034 [DOI] [PubMed] [Google Scholar]
  23. Bukhari S. N. A., Jantan I., Unsal Tan O., Sher M., Naeem-Ul-Hassan M., Qin H.-L. (2014c). Biological activity and molecular docking studies of curcumin-related α, β-unsaturated carbonyl-based synthetic compounds as anticancer agents and mushroom tyrosinase inhibitors. Agric. Food Chem. 62, 5538–5547. 10.1021/jf501145b [DOI] [PubMed] [Google Scholar]
  24. Bukhari S. N. A., Jasamai M., Jantan I. (2012). Synthesis and biological evaluation of chalcone derivatives (mini review). Mini. Rev. Med. Chem. 12, 1394–1403. 10.2174/138955712804586648 [DOI] [PubMed] [Google Scholar]
  25. Bukhari S. N. A., Franzblau S. G., Jantan I., Jasamai M. (2013a). Current prospects of synthetic curcumin analogs and chalcone derivatives against Mycobacterium tuberculosis. Med. Chem. 9, 897–903. 10.2174/1573406411309070002 [DOI] [PubMed] [Google Scholar]
  26. Bukhari S. N., Tajuddin Y., Benedict V. J., Lam K. W., Jantan I., Jalil J., et al. (2014a). Synthesis and evaluation of chalcone derivatives as inhibitors of neutrophils' chemotaxis, phagocytosis and production of reactive oxygen species. Chem. Biol. Drug Des. 83, 198–206. 10.1111/cbdd.12226 [DOI] [PubMed] [Google Scholar]
  27. Chan M. M. Y. (1995). Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem. Pharmacol. 49, 1551–1556. 10.1016/0006-2952(95)00171-U [DOI] [PubMed] [Google Scholar]
  28. Chearwae W., Bright J. J. (2008). 15-Deoxy-Δ12, 14-prostaglandin J2 and curcumin modulate the expression of toll-like receptors 4 and 9 in autoimmune T lymphocyte. J. Clin. Immunol. 28, 558–570. 10.1007/s10875-008-9202-7 [DOI] [PubMed] [Google Scholar]
  29. Chen B. Y., Lin D. P. C., Wu C. Y., Teng M. C., Sun C. Y., Tsai Y. T., et al. (2011). Dietary zerumbone prevents mouse cornea from UVB-induced photokeratitis through inhibition of NF-κB, iNOS, and TNF-α expression and reduction of MDA accumulation. Mol. Vis. 17, 854–863. [PMC free article] [PubMed] [Google Scholar]
  30. Chen B., Zhu Z., Chen M., Dong W., Li Z. (2014). Three-dimensional quantitative structure–activity relationship study on antioxidant capacity of curcumin analogues. J. Mol. Struct. 1061, 134–139. 10.1016/j.molstruc.2013.12.083 [DOI] [Google Scholar]
  31. Chiaradia L. D., Dos Santos R., Vitor C. E., Vieira A. A., Leal P. C., Nunes R. J., et al. (2008). Synthesis and pharmacological activity of chalcones derived from 2, 4, 6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure–activity relationships. Bioorg. Med. Chem. 16, 658–667. 10.1016/j.bmc.2007.10.039 [DOI] [PubMed] [Google Scholar]
  32. Chien T., Chen L., Lee C. J., Lee F., Wang C. C. (2008). Anti-inflammatory constituents of Zingiber zerumbet. Food Chem. 110, 584–589. 10.1016/j.foodchem.2008.02.038 [DOI] [Google Scholar]
  33. Choi J. M., Kim H. J., Lee K. Y., Choi H. J., Lee I. S., Kang B. Y. (2009). Increased IL-2 production in T cells by xanthohumol through enhanced NF-AT and AP-1 activity. Int. Immunopharmacol. 9, 103–107. 10.1016/j.intimp.2008.10.011 [DOI] [PubMed] [Google Scholar]
  34. Damodaran N., Dev S. (1965). Stereochemistry of zerumbone. Tetrahedron Lett. 6, 1977–1981. 10.1016/S0040-4039(01)83896-X [DOI] [Google Scholar]
  35. Datta S., Murti V., Seshadri T. (1971). Synthesis of 2'-methoxyflavanones. Indian J. Chem. 9, 614. [Google Scholar]
  36. Decoté-Ricardo D., Chagas K., Rocha J., Redner P., Lopes U., Cambier J., et al. (2009). Modulation of in vitro murine B-lymphocyte response by curcumin. Phytomedicine 16, 982–988. 10.1016/j.phymed.2009.01.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. De Leon E., Alcaraz M., Dominguez J., Charris J., Terencio M. (2003). 1-(2, 3, 4-trimethoxyphenyl)-3-(3-(2-chloroquinolinyl))-2-propen-1-one, a chalcone derivative with analgesic, anti-inflammatory and immunomodulatory properties. Inflamm. Res. 52, 246–257. 10.1007/s00011-003-1164-x [DOI] [PubMed] [Google Scholar]
  38. Deters M., Knochenwefel H., Lindhorst D., Koal T., Meyer H. H., Hänsel W., et al. (2008). Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities. Pharm. Res. 25, 1822–1827. 10.1007/s11095-008-9579-2 [DOI] [PubMed] [Google Scholar]
  39. Dev S. (1960). Studies in sesquiterpenes—XVI: Zerumbone, a monocyclic sesquiterpene ketone. Tetrahedron 8, 171–180. 10.1016/0040-4020(60)80027-0 [DOI] [Google Scholar]
  40. Du Z. Y., Wei X., Huang M. T., Zheng X., Liu Y., Conney A. H., et al. (2013). Anti-proliferative, anti-inflammatory and antioxidant effects of curcumin analogue A2. Arch. Pharmacol. Res. 36, 1204–1210. 10.1007/s12272-013-0216-1 [DOI] [PubMed] [Google Scholar]
  41. Eguchi A., Kaneko Y., Murakami A., Ohigashi H. (2007). Zerumbone suppresses phorbol ester-induced expression of multiple scavenger receptor genes in THP-1 human monocytic cells. Biosci. Biotechnol. Biochem. 71, 935–945. 10.1271/bbb.60596 [DOI] [PubMed] [Google Scholar]
  42. Fahey A. J., Adrian Robins R., Constantinescu C. S. (2007). Curcumin modulation of IFN-β and IL-12 signalling and cytokine induction in human T cells. J. Cell Mol. Med. 11, 1129–1137. 10.1111/j.1582-4934.2007.00089.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Fang F., Tang Y., Gao Z., Xu Q. (2010). A novel regulatory mechanism of naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochem. Biophys. Res. Commun. 397, 163–169. 10.1016/j.bbrc.2010.05.065 [DOI] [PubMed] [Google Scholar]
  44. Faudzi S. M., Leong S., Abas F., Aluwi M. M., Rullah K., Lam K., et al. (2015). Synthesis, biological evaluation and QSAR studies of diarylpentanoid analogues as potential nitric oxide inhibitors. Med. Chem. Commun. 6, 1069–1080. 10.1039/C4MD00541D [DOI] [Google Scholar]
  45. Feng R., Lu Y., Bowman L. L., Qian Y., Castranova V., Ding M. (2005). Inhibition of activator protein-1, NF-κB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 280, 27888–27895. 10.1074/jbc.M503347200 [DOI] [PubMed] [Google Scholar]
  46. Franck T., Kohnen S., Grulke S., Neven P., Goutman Y., Péters F., et al. (2008). Inhibitory effect of curcuminoids and tetrahydrocurcuminoids on equine activated neutrophils and myeloperoxidase activity. Physiol. Res. 57, 577–587. [DOI] [PubMed] [Google Scholar]
  47. Ganabadi S., Kadir S. F. A. (2009). ZiTumboiHi's effect on major histocompatibility complex type II cells in synovial membrane of OsteoArthritic Joint. J. Vet. Sci. 2, 14–20. [Google Scholar]
  48. Gao X., Deeb D., Liu Y., Gautam S., Dulchavsky S. A., Gautam S. C. (2009). Immunomodulatory activity of xanthohumol: inhibition of T cell proliferation, cell-mediated cytotoxicity and Th1 cytokine production through suppression of NF-κB. Immunopharmacol. Immunotoxicol. 31, 477–484. 10.1080/08923970902798132 [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gao X., Kuo J., Jiang H., Deeb D., Liu Y., Divine G., et al. (2004). Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro. Biochem. Pharmacol. 68, 51–61. 10.1016/j.bcp.2004.03.015 [DOI] [PubMed] [Google Scholar]
  50. Gea-Banacloche J. C. (2006). Immunomodulation, in Principles of Molecular Medicine, eds Runge M. S., Patterson C.(Totowa, NJ: Springer; ), 893–904. [Google Scholar]
  51. Giang P., Jin H., Lee J., Lee J. (2009). Comparative study on inhibitory activity of zerumbone and zerumbone 2, 3-epoxide on NF-kB activation and NO production. Sci. Pharm. 77, 589–595. 10.3797/scipharm.0907-16 [DOI] [Google Scholar]
  52. Giri R. K., Rajagopal V., Kalra V. K. (2004). Curcumin, the active constituent of turmeric, inhibits amyloid peptide-induced cytochemokine gene expression and CCR5-mediated chemotaxis of THP-1 monocytes by modulating early growth response-1 transcription factor. J. Neurochem. 91, 1199–1210. 10.1111/j.1471-4159.2004.02800.x [DOI] [PubMed] [Google Scholar]
  53. Goodarzi M., Saeys W., De Araujo M. C. U., Galvão R. K. H., Vander Heyden Y. (2014). Binary classification of chalcone derivatives with LDA or KNN based on their antileishmanial activity and molecular descriptors selected using the successive projections algorithm feature-selection technique. Eur. J. Pharm. Sci. 51, 189–195. 10.1016/j.ejps.2013.09.019 [DOI] [PubMed] [Google Scholar]
  54. Hamaguchi T., Ono K., Yamada M. (2010). REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci. Ther. 16, 285–297. 10.1111/j.1755-5949.2010.00147.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Han S. S., Chung S. T., Robertson D. A., Ranjan D., Bondada S. (1999). Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-X L, NF-κB, and p53. Clin. Immunol. 93, 152–161. 10.1006/clim.1999.4769 [DOI] [PubMed] [Google Scholar]
  56. Haque S., Lee H., Waqas B., Chiorazzi N., Mongini P. (2010). Anti-inflammatory curcumin inhibits AID expression within cycling human B cells (96.21). J. Immunol. 184, 96.21-96.21. [Google Scholar]
  57. Hatziieremia S., Gray A., Ferro V., Paul A., Plevin R. (2006). The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFκB signalling pathways in monocytes/macrophages. Br. J. Pharmacol. 149, 188–198. 10.1038/sj.bjp.0706856 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Herencia F., Ferrándiz M. L., Ubeda A., Guillén I., Dominguez J. N., Charris J. E., et al. (2001). 4-dimethylamino-3′, 4′-dimethoxychalcone downregulates iNOS expression and exerts anti-inflammatory effects. Free Radic. Biol. Med. 30, 43–50. 10.1016/S0891-5849(00)00443-3 [DOI] [PubMed] [Google Scholar]
  59. Hirai S., Kim Y. I., Goto T., Kang M. S., Yoshimura M., Obata A., et al. (2007). Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Sci. 81, 1272–1279. 10.1016/j.lfs.2007.09.001 [DOI] [PubMed] [Google Scholar]
  60. Hong J., Bose M., Ju J., Ryu J. H., Chen X., Sang S., et al. (2004). Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25, 1671–1679. 10.1093/carcin/bgh165 [DOI] [PubMed] [Google Scholar]
  61. Hornung R., Back T., Zaharko D., Urba W., Longo D., Wiltrout R. (1988). Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2. J. Immunol. 141, 3671–3679. [PubMed] [Google Scholar]
  62. Hsieh H. K., Lee T. H., Wang J. P., Wang J. J., Lin C. N. (1998). Synthesis and anti-inflammatory effect of chalcones and related compounds. Pharm. Res. 15, 39–46. 10.1023/A:1011940401754 [DOI] [PubMed] [Google Scholar]
  63. Hwang T. L., Leu Y. L., Kao S. H., Tang M. C., Chang H. L. (2006). Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway. Free Radic. Biol. Med. 41, 1433–1441. 10.1016/j.freeradbiomed.2006.08.001 [DOI] [PubMed] [Google Scholar]
  64. Igarashi Y., Ohnishi K., Irie K., Murakami A. (2016). Possible contribution of zerumbone-induced proteo-stress to its anti-inflammatory functions via the activation of heat shock factor 1. PLoS ONE 11:e0161282. 10.1371/journal.pone.0161282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Ilangkovan M., Jantan I., Mesaik M. A., Bukhari S. N. A. (2015). Immunosuppressive effects of the standardized extract of Phyllanthus amarus on cellular immune responses in Wistar-Kyoto rats. Drug Des. Dev. Ther. 9, 4917. 10.2147/DDDT.S88189 [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Itoh T., Ninomiya M., Nozawa Y., Koketsu M. (2010). Chalcone glycosides isolated from aerial parts of Brassica rapa L. “hidabeni” suppress antigen-stimulated degranulation in rat basophilic leukemia RBL-2H3 cells. Bioorg. Med. Chem. 18, 7052–7057. 10.1016/j.bmc.2010.08.008 [DOI] [PubMed] [Google Scholar]
  67. Iwamura C., Shinoda K., Yoshimura M., Watanabe Y., Obata A., Nakayama T. (2010). Naringenin chalcone suppresses allergic asthma by inhibiting the type-2 function of CD4 T cells. Allergo. Int. 59, 67–73. 10.2332/allergolint.09-OA-0118 [DOI] [PubMed] [Google Scholar]
  68. Jackson J., Higo T., Hunter W., Burt H. (2006). The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm. Res. 55, 168–175. 10.1007/s00011-006-0067-z [DOI] [PubMed] [Google Scholar]
  69. Jagetia G. C., Aggarwal B. B. (2007). “Spicing up” of the immune system by curcumin. J. Clin. Immunol. 27, 19–35. 10.1007/s10875-006-9066-7 [DOI] [PubMed] [Google Scholar]
  70. Jain S. K., Rains J., Croad J., Larson B., Jones K. (2009). Curcumin supplementation lowers TNF-α, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-α, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid. Redox Signal. 11, 241–249. 10.1089/ars.2008.2140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Jančinová V., Perečko T., Nosál R., Košt'álová D., Bauerová K., Drábiková K. (2009). Decreased activity of neutrophils in the presence of diferuloylmethane (curcumin) involves protein kinase C inhibition. Eur. J. Pharmacol. 612, 161–166. 10.1016/j.ejphar.2009.03.080 [DOI] [PubMed] [Google Scholar]
  72. Jang D. S., Min H. Y., Kim M. S., Han A. R., Windono T., Jeohn G. H., et al. (2005). Humulene derivatives from Zingiber zerumbet with the inhibitory effects on lipopolysaccharide-induced nitric oxide production. Chem. Pharm. Bull. 53, 829–831. 10.1248/cpb.53.829 [DOI] [PubMed] [Google Scholar]
  73. Jantan I., Bukhari S. N. A., Adekoya O. A., Sylte I. (2014). Studies of synthetic chalcone derivatives as potential inhibitors of secretory phospholipase A2, cyclooxygenases, lipoxygenase and pro-inflammatory cytokines. Drug Des. Dev. Ther. 8, 1405. 10.2147/DDDT.S67370 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Jantan I., Bukhari S. N. A., Lajis N. H., Abas F., Wai L. K., Jasamai M. (2012). Effects of diarylpentanoid analogues of curcumin on chemiluminescence and chemotactic activities of phagocytes. J. Pharm. Pharmacol. 64, 404–412. 10.1111/j.2042-7158.2011.01423.x [DOI] [PubMed] [Google Scholar]
  75. Jeong Y. I., Kim S. W., Jung I. D., Lee J. S., Chang J. H., Lee C. M., et al. (2009). Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janus-activated kinase-protein kinase Cδ-STAT1 signaling pathway in interferon-γ-stimulated murine dendritic cells. J. Biol. Chem. 284, 3700–3708. 10.1074/jbc.M.807328200 [DOI] [PubMed] [Google Scholar]
  76. Keong Y. S., Alitheen N. B., Mustafa S., Aziz S. A., Rahman M. A., Ali A. M. (2010). Immunomodulatory effects of zerumbone isolated from roots of Zingiber zerumbet. Pak. J. Pharm. Sci. 23, 75–82. [PubMed] [Google Scholar]
  77. Kil J. S., Son Y., Cheong Y. K., Kim N. H., Jeong H. J., Kwon J. W., et al. (2011). Okanin, a chalcone found in the genus Bidens, and 3-penten-2-one inhibit inducible nitric oxide synthase expression via heme oxygenase-1 induction in RAW264. 7 macrophages activated with lipopolysaccharide. J Clin. Biochem. Nutr. 50, 53–58. 10.3164/jcbn.11-30 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Kim A. N., Jeon W. K., Lee J. J., Kim B. C. (2010). Up-regulation of heme oxygenase-1 expression through CaMKII-ERK1/2-Nrf2 signaling mediates the anti-inflammatory effect of bisdemethoxycurcumin in LPS-stimulated macrophages. Free Radic. Biol. Med. 49, 323–331. 10.1016/j.freeradbiomed.2010.04.015 [DOI] [PubMed] [Google Scholar]
  79. Kim G. Y., Kim K.-H., Lee S. H., Yoon M. S., Lee H. J., Moon D. O., et al. (2005). Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-κB as potential targets. J. Immunol. 174, 8116–8124. 10.4049/jimmunol.174.12.8116 [DOI] [PubMed] [Google Scholar]
  80. Kim K. N., Ko Y. J., Kang M. C., Yang H. M., Roh S. W., Oda T., et al. (2013). Anti-inflammatory effects of trans-1, 3-diphenyl-2, 3-epoxypropane-1-one mediated by suppression of inflammatory mediators in LPS-stimulated RAW 264.7 macrophages. Food Chem. Toxicol. 53, 371–375. 10.1016/j.fct.2012.12.021 [DOI] [PubMed] [Google Scholar]
  81. Kimura Y., Okuda H., Okuda T., Arichi S. (1988). Effects of chalcones isolated from licorice roots on leukotriene biosynthesis in human polymorphonuclear neutrophls. Phytother. Res. 2, 140–145. 10.1002/ptr.2650020308 [DOI] [Google Scholar]
  82. Ko H. H., Tsao L. T., Yu K. L., Liu C. T., Wang J. P., Lin C. N. (2003). Structure–activity relationship studies on chalcone derivatives: the potent inhibition of chemical mediators release. Bioorg. Med. Chem. 11, 105–111. 10.1016/S0968-0896(02)00312-7 [DOI] [PubMed] [Google Scholar]
  83. Kolbe L., Immeyer J., Batzer J., Wensorra U., Tom Dieck K., Mundt C., et al. (2006). Anti-inflammatory efficacy of Licochalcone A: correlation of clinical potency and in vitro effects. Arch. Dermatol. Res. 298, 23–30. 10.1007/s00403-006-0654-4 [DOI] [PubMed] [Google Scholar]
  84. Sahu N. K., Balbhadra S. S., Choudhary J., Kohli D. V. (2012). Exploring pharmacological significance of chalcone scaffold: a review. Curr. Med. Chem. 19, 209–225. 10.2174/092986712803414132 [DOI] [PubMed] [Google Scholar]
  85. Kumar A., Dhawan S., Hardegen N. J., Aggarwal B. B. (1998). Curcumin (diferuloylmethane) inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-κB activation. Biochem. Pharmacol. 55, 775–783. 10.1016/S0006-2952(97)00557-1 [DOI] [PubMed] [Google Scholar]
  86. Kuramoto Y., Yamada K., Tsuruta O., Sugano M. (1996). Effect of natural food colorings on immunoglobulin production in vitro by rat spleen lymphocytes. Biosci. Biotechnol. Bochem. 60, 1712–1713. 10.1271/bbb.60.1712 [DOI] [PubMed] [Google Scholar]
  87. Kurup V. P., Barrios C. S. (2008). Immunomodulatory effects of curcumin in allergy. Mol. Nutr. Food Res. 52, 1031–1039. 10.1002/mnfr.200700293 [DOI] [PubMed] [Google Scholar]
  88. Lai J. J., Lai K. P., Chuang K. H., Chang P., Yu I. C., Lin W. J., et al. (2009). Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-α expression. J. Clin. Invest. 119, 3739. 10.1172/JCI39335 [DOI] [PMC free article] [PubMed] [Google Scholar]
  89. Lal J., Gupta S., Thavaselvam D., Agarwal D. (2012). Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3, 4-dihydropyrimidinones of curcumin. Bioorg. Med. Chem. Lett. 22, 2872–2876. 10.1016/j.bmcl.2012.02.056 [DOI] [PubMed] [Google Scholar]
  90. Larmonier C. B., Uno J. K., Lee K. M., Karrasch T., Laubitz D., Thurston R., et al. (2008). Limited effects of dietary curcumin on Th-1 driven colitis in IL-10 deficient mice suggest an IL-10-dependent mechanism of protection. Am. J. Physiol. Gastrointest. Liver. Physiol. 295, G1079–G1091. 10.1152/ajpgi.90365.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Lee J. H., Kim J. W., Ko N. Y., Mun S. H., Her E., Kim B. K., et al. (2008). Curcumin, a constituent of curry, suppresses IgE-mediated allergic response and mast cell activation at the level of Syk. J. Allergy Clin. Immunol. 121, 1225–1231. 10.1016/j.jaci.2007.12.1160 [DOI] [PubMed] [Google Scholar]
  92. Lee J. S., Bukhari S. N. A., Fauzi N. M. (2015). Effects of chalcone derivatives on players of the immune system. Drug Des. Dev. Ther. 9, 4761. 10.2147/DDDT.S86242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Lee K. H., Aziz F. H. A., Syahida A., Abas F., Shaari K., Israf D. A., et al. (2009). Synthesis and biological evaluation of curcumin-like diarylpentanoid analogues for anti-inflammatory, antioxidant and anti-tyrosinase activities. Eur. J. Med. Chem. 44, 3195–3200. 10.1016/j.ejmech.2009.03.020 [DOI] [PubMed] [Google Scholar]
  94. Lee S. H., Seo G. S., Kim J. Y., Jin X. Y., Kim H. D., Sohn D. H. (2006). Heme oxygenase 1 mediates anti-inflammatory effects of 2′, 4′, 6′-tris (methoxymethoxy) chalcone. Eur. J. Pharmacol. 532, 178–186. 10.1016/j.ejphar.2006.01.005 [DOI] [PubMed] [Google Scholar]
  95. Lee S. L., Huang W. J., Lin W. W., Lee S. S., Chen C. H. (2005). Preparation and anti-inflammatory activities of diarylheptanoid and diarylheptylamine analogs. Bioorg. Med. Chem. 13, 6175–6181. 10.1016/j.bmc.2005.06.058 [DOI] [PubMed] [Google Scholar]
  96. Leong S. W., Faudzi S. M. M., Abas F., Aluwi M. F. F. M., Rullah K., Lam K. W., et al. (2015). Nitric oxide inhibitory activity and antioxidant evaluations of 2-benzoyl-6-benzylidenecyclohexanone analogs, a novel series of curcuminoid and diarylpentanoid derivatives. Bioorg. Med. Chem. Lett. 25, 3330–3337. 10.1016/j.bmcl.2015.05.056 [DOI] [PubMed] [Google Scholar]
  97. Leong S. W., Faudzi S. M. M., Abas F., Aluwi M. F. F. M., Rullah K., Wai L. K., et al. (2014). Synthesis and sar study of diarylpentanoid analogues as new anti-inflammatory agents. Molecules 19, 16058–16081. 10.3390/molecules191016058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Lian Q., Li X., Shang Y., Yao S., Ma L., Jin S. (2006). Protective effect of curcumin on endotoxin-induced acute lung injury in rats. J. Huazhong Univ. Sci. Technol. Med. Sci. 26, 678–681. 10.1007/s11596-006-0613-5 [DOI] [PubMed] [Google Scholar]
  99. Liang G., Yang S., Zhou H., Shao L., Huang K., Xiao J., et al. (2009a). Synthesis, crystal structure and anti-inflammatory properties of curcumin analogues. Eur. J. Med. Chem. 44, 915–919. 10.1016/j.ejmech.2008.01.031 [DOI] [PubMed] [Google Scholar]
  100. Liang G., Zhou H., Wang Y., Gurley E. C., Feng B., Chen L., et al. (2009b). Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin. J. Cell Mol. Med. 13, 3370–3379. 10.1111/j.1582-4934.2009.00711.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Liew C. Y., Lam K. W., Kim M. K., Harith H. H., Tham C. L., Cheah Y. K., et al. (2011). Effects of 3-(2-Hydroxyphenyl)-1-(5-methyl-furan-2-yl) propenone (HMP) upon signalling pathways of lipopolysaccharide-induced iNOS synthesis in RAW 264.7 cells. Int. Immunopharmacol. 11, 85–95. 10.1016/j.intimp.2010.10.011 [DOI] [PubMed] [Google Scholar]
  102. Lim J. H., Kwon T. K. (2010). Curcumin inhibits phorbol myristate acetate (PMA)-induced MCP-1 expression by inhibiting ERK and NF-κB transcriptional activity. Food Chem. Toxicol. 48, 47–52. 10.1016/j.fct.2009.09.013 [DOI] [PubMed] [Google Scholar]
  103. Lin Y. M., Zhou Y., Flavin M. T., Zhou L. M., Nie W., Chen F. C. (2002). Chalcones and flavonoids as anti-tuberculosis agents. Bioorg. Med. Chem. 10, 2795–2802. 10.1016/S0968-0896(02)00094-9 [DOI] [PubMed] [Google Scholar]
  104. Madan B., Ghosh B. (2003). Diferuloylmethane inhibits neutrophil infiltration and improves survival of mice in high-dose endotoxin shock. Shock 19, 91–96. 10.1097/00024382-200301000-00017 [DOI] [PubMed] [Google Scholar]
  105. Magalska A., Brzezinska A., Bielak-Zmijewska A., Piwocka K., Mosieniak G., Sikora E. (2006). Curcumin induces cell death without oligonucleosomal DNA fragmentation in quiescent and proliferating human CD8+ cells. Acta. Biochim. Pol. 53, 531. [PubMed] [Google Scholar]
  106. Magerramov A., Kurbanova M., Abdinbekova R., Rzaeva I., Farzaliev V., Allakhverdiev M. (2006). Synthesis and antioxidative properties of some 3, 4-dihydropyrimidin-2 (1H) ones (-thiones). Russ. J. Appl. Chem. 79, 787–790. 10.1134/S107042720605017X [DOI] [Google Scholar]
  107. Maier E., Kurz K., Jenny M., Schennach H., Ueberall F., Fuchs D. (2010). Food preservatives sodium benzoate and propionic acid and colorant curcumin suppress Th1-type immune response in vitro. Food Chem. Toxicol. 48, 1950–1956. 10.1016/j.fct.2010.04.042 [DOI] [PubMed] [Google Scholar]
  108. Makrandi J., Kumar S. (2004). An efficient synthesis of 2'-Hydroxychalcones. Asian J. Chem. 16, 1189. [Google Scholar]
  109. Mandal A., Viswanathan C. (2015). Natural killer cells: in health and disease. Hematol. Oncol. Stem. Cell Ther. 8, 47–55. 10.1016/j.hemonc.2014.11.006 [DOI] [PubMed] [Google Scholar]
  110. Maradana M. R., Thomas R., O'sullivan B. J. (2013). Targeted delivery of curcumin for treating type 2 diabetes. Mol. Nutr. Food Res. 57, 1550–1556. 10.1002/mnfr.201200791 [DOI] [PubMed] [Google Scholar]
  111. Matsuguchi T., Musikacharoen T., Ogawa T., Yoshikai Y. (2000). Gene expressions of Toll-like receptor 2, but not Toll-like receptor 4, is induced by LPS and inflammatory cytokines in mouse macrophages. J. Immunol. 165, 5767–5772. 10.4049/jimmunol.165.10.5767 [DOI] [PubMed] [Google Scholar]
  112. McDonald J., Rhoads J., Siquijor A. (1998). The effect of curcumin on human B-cell immortalization by Epstein-Barr virus-Discussion. Am. Surg. 64, 47–51. [PubMed] [Google Scholar]
  113. Mehrotra S., Agnihotri G., Singh S., Jamal F. (2013). Immunomodulatory potential of Curcuma longa: a review. South Asian J. Exp. Biol. 3, 299–307. [Google Scholar]
  114. Middleton E., Drzewiecki G. (1984). Flavonoid inhibition of human basophil histamine release stimulated by various agents. Biochem. Pharmacol. 33, 3333–3338. 10.1016/0006-2952(84)90102-3 [DOI] [PubMed] [Google Scholar]
  115. Min H. Y., Kim M. S., Jang D. S., Park E. J., Seo E. K., Lee S. K. (2009). Suppression of lipopolysaccharide-stimulated inducible nitric oxide synthase (iNOS) expression by a novel humulene derivative in macrophage cells. Int. Immunopharmacol. 9, 844–849. 10.1016/j.intimp.2009.03.005 [DOI] [PubMed] [Google Scholar]
  116. Moon D. O., Kim M. O., Choi Y. H., Park Y. M., Kim G. Y. (2010). Curcumin attenuates inflammatory response in IL-1β-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int. Immunopharmacol. 10, 605–610. 10.1016/j.intimp.2010.02.011 [DOI] [PubMed] [Google Scholar]
  117. Moon D. O., Kim M. O., Lee H. J., Choi Y. H., Park Y. M., Heo M. S., et al. (2008). Curcumin attenuates ovalbumin-induced airway inflammation by regulating nitric oxide. Biochem. Biophys. Res. Commun. 375, 275–279. 10.1016/j.bbrc.2008.08.025 [DOI] [PubMed] [Google Scholar]
  118. Murakami A., Miyamoto M., Ohigashi H. (2004). Zerumbone, an anti-inflammatory phytochemical, induces expression of proinflammatory cytokine genes in human colon adenocarcinoma cell lines. Biofactors 21, 95–101. 10.1002/biof.552210118 [DOI] [PubMed] [Google Scholar]
  119. Murakami A., Shigemori T., Ohigashi H. (2005). Zingiberaceous and citrus constituents, 1′-acetoxychavicol acetate, zerumbone, auraptene, and nobiletin, suppress lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264. 7 murine macrophages through different modes of action. J. Nutr. 135, 2987S–2992S. [DOI] [PubMed] [Google Scholar]
  120. Murakami A., Takahashi D., Kinoshita T., Koshimizu K., Kim H. W., Yoshihiro A., et al. (2002). Zerumbone, a Southeast Asian ginger sesquiterpene, markedly suppresses free radical generation, proinflammatory protein production, and cancer cell proliferation accompanied by apoptosis: the α, β-unsaturated carbonyl group is a prerequisite. Carcinogenesis 23, 795–802. 10.1093/carcin/23.5.795 [DOI] [PubMed] [Google Scholar]
  121. Namgoong S., Son K., Chang H., Kang S., Kim H. (1994). Effects of naturally occurring flavonoids on mitogen-induced lymphocyte proliferation and mixed lymphocyte culture. Life Sci. 54, 313–320. 10.1016/0024-3205(94)00787-X [DOI] [PubMed] [Google Scholar]
  122. Natarajan C., Bright J. J. (2002). Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 168, 6506–6513. 10.4049/jimmunol.168.12.6506 [DOI] [PubMed] [Google Scholar]
  123. Ohnishi K., Irie K., Murakami A. (2009). In vitro covalent binding proteins of zerumbone, a chemopreventive food factor. Biosci. Biotechnol. Biochem. 73, 1905–1907. 10.1271/bbb.90265 [DOI] [PubMed] [Google Scholar]
  124. Ou J. L., Mizushina Y., Wang S. Y., Chuang D. Y., Nadar M., Hsu W. L. (2013). Structure–activity relationship analysis of curcumin analogues on anti-influenza virus activity. FEBS J. 280, 5829–5840. 10.1111/febs.12503 [DOI] [PubMed] [Google Scholar]
  125. Pae H. O., Jeong S. O., Kim H. S., Kim S. H., Song Y. S., Kim S. K., et al. (2008). Dimethoxycurcumin, a synthetic curcumin analogue with higher metabolic stability, inhibits NO production, inducible NO synthase expression and NF-κB activation in RAW264. 7 macrophages activated with LPS. Mol. Nutr. Food Res. 52, 1082–1091. 10.1002/mnfr.200700333 [DOI] [PubMed] [Google Scholar]
  126. Park P.-H., Kim H. S., Jin X. Y., Jin F., Hur J., Ko G., et al. (2009). KB-34, a newly synthesized chalcone derivative, inhibits lipopolysaccharide-stimulated nitric oxide production in RAW 264.7 macrophages via heme oxygenase-1 induction and blockade of activator protein-1. Eur. J. Pharmacol. 606, 215–224. [DOI] [PubMed] [Google Scholar]
  127. Platt C. D., Ma J. K., Chalouni C., Ebersold M., Bou-Reslan H., Carano R. A., et al. (2010). Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl. Acad. Sci. U.S.A. 107, 4287–4292. 10.1073/pnas.0910609107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Qin H.-L., Leng J., Zhang C.-P., Jantan I., Amjad M. W., Sher M., et al. (2016). Synthesis of α, β-unsaturated carbonyl-based compounds, oxime and oxime ether analogs as potential anticancer agents for overcoming cancer multidrug resistance by modulation of efflux pumps in tumor cells. J. Med. Chem. 59, 3549–3561. 10.1021/acs.jmedchem.6b00276 [DOI] [PubMed] [Google Scholar]
  129. Rahman H. S., Rasedee A., How C. W., Abdul A. B., Zeenathul N. A., Othman H. H., et al. (2013). Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect. Int. J. Nanomed. 8, 2769. 10.2147/IJN.S45313 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Rahman H. S., Rasedee A., Chartrand M. S., Othman H. H., Yeap S. K., Namvar F. (2014). Zerumbone induces G2/M cell cycle arrest and apoptosis via mitochondrial pathway in Jurkat cell line. Nat. Prod. Commun. 9, 1237–1242. 10.2147/IJN.S54346 [DOI] [PubMed] [Google Scholar]
  131. Raine C. S. (1990). Multiple sclerosis: immunopathologic mechanisms in the progression and resolution of inflammatory demyelination. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 68, 37. [PubMed] [Google Scholar]
  132. Ranjan D., Chen C., Johnston T. D., Jeon H., Nagabhushan M. (2004). Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFκB activation, and IL-2 signaling. J. Surg. Res. 121, 171–177. 10.1016/j.jss.2004.04.004 [DOI] [PubMed] [Google Scholar]
  133. Ranjan D., Johnston T. D., Reddy K. S., Wu G., Bondada S., Chen C. (1999). Enhanced apoptosis mediates inhibition of EBV-transformed lymphoblastoid cell line proliferation by curcumin. J. Surg. Res. 87, 1–5. 10.1006/jsre.1999.5719 [DOI] [PubMed] [Google Scholar]
  134. Ranjan D., Johnston T. D., Wu G., Elliott L., Bondada S., Nagabhushan M. (1998). Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. J. Surg. Res. 77, 174–178. 10.1006/jsre.1998.5374 [DOI] [PubMed] [Google Scholar]
  135. Reddy M. V. B., Hwang T. L., Leu Y. L., Chiou W. F., Wu T. S. (2011). Inhibitory effects of Mannich bases of heterocyclic chalcones on NO production by activated RAW 264.7 macrophages and superoxide anion generation and elastase release by activated human neutrophils. Bioorg. Med. Chem. 19, 2751–2756. 10.1016/j.bmc.2011.02.038 [DOI] [PubMed] [Google Scholar]
  136. Rodrigues T., Reker D., Schneider P., Schneider G. (2016). Counting on natural products for drug design. Nat. Chem. 8, 531–541. 10.1038/nchem.2479 [DOI] [PubMed] [Google Scholar]
  137. Roh E., Lee H. S., Kwak J. A., Hong J. T., Nam S. Y., Jung S. H., et al. (2011). MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. J. Infect. Dis. 203, 1012–1020. 10.1093/infdis/jiq155 [DOI] [PubMed] [Google Scholar]
  138. Schwartz A., Middleton E. (1984). Comparison of the effects of quercetin with those of other flavonoids on the generation and effector function of cytotoxic T lymphocytes. Immunopharmacology 7, 115–126. 10.1016/0162-3109(84)90061-4 [DOI] [PubMed] [Google Scholar]
  139. Sciullo E. M., Vogel C. F., Wu D., Murakami A., Ohigashi H., Matsumura F. (2010). Effects of selected food phytochemicals in reducing the toxic actions of TCDD and p, p′-DDT in U937 macrophages. Arch. Toxicol. 84, 957–966. 10.1007/s00204-010-0592-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Sharma S., Chopra K., Kulkarni S., Agrewala J. (2007). Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin. Exp. Immunol. 147, 155–163. 10.1111/j.1365-2249.2006.03257.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Shieh Y. H., Huang H. M., Wang C. C., Lee C. C., Fan C. K., Lee Y. L. (2015). Zerumbone enhances the Th1 response and ameliorates ovalbumin-induced Th2 responses and airway inflammation in mice. Int. Immunopharmacol. 24, 383–391. 10.1016/j.intimp.2014.12.027 [DOI] [PubMed] [Google Scholar]
  142. Shirley S. A., Montpetit A. J., Lockey R., Mohapatra S. S. (2008). Curcumin prevents human dendritic cell response to immune stimulants. Biochem. Biophys. Res. Commun. 374, 431–436. 10.1016/j.bbrc.2008.07.051 [DOI] [PMC free article] [PubMed] [Google Scholar]
  143. Sikora E., Bielak-Żmijewska A., Magalska A., Piwocka K., Mosieniak G., Kalinowska M., et al. (2006). Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. Mol. Cancer Ther. 5, 927–934. 10.1158/1535-7163.MCT-05-0360 [DOI] [PubMed] [Google Scholar]
  144. Sikora E., Bielak-Zmijewska A., Piwocka K., Janusz S., Radziszewska E. (1997). Inhibition of proliferation and apoptosis of human and rat T lymphocytes by curcumin, a curry pigment. Biochem. Pharmacol. 54, 899–907. 10.1016/S0006-2952(97)00251-7 [DOI] [PubMed] [Google Scholar]
  145. Silva D., Chioua M., Samadi A., Agostinho P., Garçã O. P., Lajarín-Cuesta R., et al. (2013). Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-Induced neurotoxicity. ACS Chem. Neurosci. 4, 547–565. 10.1021/cn300178k [DOI] [PMC free article] [PubMed] [Google Scholar]
  146. Sivakumar P., Seenivasan S. P., Kumar V., Doble M. (2007). Synthesis, antimycobacterial activity evaluation, and QSAR studies of chalcone derivatives. Bioorg. Med. Chem. Lett. 17, 1695–1700. 10.1016/j.bmcl.2006.12.112 [DOI] [PubMed] [Google Scholar]
  147. South E., Exon J., Hendrix K. (1997). Dietary curcumin enhances antibody response in rats. Immunopharmacol. Immunotoxicol. 19, 105–119. 10.3109/08923979709038536 [DOI] [PubMed] [Google Scholar]
  148. Srivastava R. (1989). Inhibition of neutrophil response by curcumin. Agents Actions 28, 298–303. 10.1007/BF01967418 [DOI] [PubMed] [Google Scholar]
  149. Steele V. E., Kelloff G. J., Wilkinson B. P., Arnold J. T. (1990). Inhibition of transformation in cultured rat tracheal epithelial cells by potential chemopreventive agents. Cancer Res. 50, 2068–2074. [PubMed] [Google Scholar]
  150. Sulaiman M. R., Perimal E. K., Akhtar M. N., Mohamad A., Khalid M. H., Tasrip N. A., et al. (2010). Anti-inflammatory effect of zerumbone on acute and chronic inflammation models in mice. Fitoterapia 81, 855–858. 10.1016/j.fitote.2010.05.009 [DOI] [PubMed] [Google Scholar]
  151. Sumanont Y., Murakami Y., Tohda M., Vajragupta O., Matsumoto K., Watanabe H. (2004). Evaluation of the nitric oxide radical scavenging activity of manganese complexes of curcumin and its derivative. Biol. Pharm. Bull. 27, 170–173. 10.1248/bpb.27.170 [DOI] [PubMed] [Google Scholar]
  152. Sung B., Murakami A., Oyajobi B. O., Aggarwal B. B. (2009). Zerumbone abolishes RANKL-induced NF-κB activation, inhibits osteoclastogenesis, and suppresses human breast cancer–induced bone loss in athymic nude mice. Cancer Res. 69, 1477–1484. 10.1158/0008-5472.CAN-08-3249 [DOI] [PubMed] [Google Scholar]
  153. Syahida A., Israf D., Lajis N., Khozirah S., Jasril M. H., Permana D., et al. (2006). Effect of compounds isolated from natural products on IFN-γ/LPS–induced nitric oxide production in RAW 264.7 macrophages. Pharm. Biol. 44, 50–59. 10.1080/13880200500530765 [DOI] [Google Scholar]
  154. Takahashi M., Ishiko T., Kamohara H., Hidaka H., Ikeda O., Ogawa M., et al. (2007). Curcumin (1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) blocks the chemotaxis of neutrophils by inhibiting signal transduction through IL-8 receptors. Mediators Inflamm. 2007:10767. 10.1155/2007/10767 [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Tanaka H., Nakamura S., Onda K., Tazaki T., Hirano T. (2009). Sofalcone, an anti-ulcer chalcone derivative, suppresses inflammatory crosstalk between macrophages and adipocytes and adipocyte differentiation: implication of heme-oxygenase-1 induction. Biochem. Biophys. Res. Commun. 381, 566–571. 10.1016/j.bbrc.2009.02.086 [DOI] [PubMed] [Google Scholar]
  156. Tanifuji S., Aizu-Yokota E., Funakoshi-Tago M., Sonoda Y., Inoue H., Kasahara T. (2010). Licochalcones suppress degranulation by decreasing the intracellular Ca 2+ level and tyrosine phosphorylation of ERK in RBL-2H3 cells. Int. Immunopharmacol. 10, 769–776. 10.1016/j.intimp.2010.04.007 [DOI] [PubMed] [Google Scholar]
  157. Tomar V., Bhattacharjee G., Kumar A. (2007). Synthesis and antimicrobial evaluation of new chalcones containing piperazine or 2, 5-dichlorothiophene moiety. Bioorg. Med. Chem. Lett. 17, 5321–5324. 10.1016/j.bmcl.2007.08.021 [DOI] [PubMed] [Google Scholar]
  158. Trivedi J. C., Bariwal J. B., Upadhyay K. D., Naliapara Y. T., Joshi S. K., Pannecouque C. C., et al. (2007). Improved and rapid synthesis of new coumarinyl chalcone derivatives and their antiviral activity. Tetrahedron Lett. 48, 8472–8474. 10.1016/j.tetlet.2007.09.175 [DOI] [Google Scholar]
  159. Varalakshmi C., Ali A. M., Pardhasaradhi B., Srivastava R. M., Singh S., Khar A. (2008). Immunomodulatory effects of curcumin: in-vivo. Int. Immunopharmacol. 8, 688–700. 10.1016/j.intimp.2008.01.008 [DOI] [PubMed] [Google Scholar]
  160. Verma A. K., Johnson J. A., Gould M. N., Tanner M. A. (1988). Inhibition of 7, 12-dimethylbenz (a) anthracene-and N-nitrosomethylurea-induced rat mammary cancer by dietary flavonol quercetin. Cancer Res. 48, 5754–5758. [PubMed] [Google Scholar]
  161. Wang J. P., Chang L. C., Hsu M. F., Lin C. N. (2003). The blockade of formyl peptide-induced respiratory burst by 2', 5'-dihydroxy-2-furfurylchalcone involves phospholipase D signaling in neutrophils. Naunyn-Schmiedeberg's Arch. Pharmacol. 368, 166–174. 10.1007/s00210-003-0782-8 [DOI] [PubMed] [Google Scholar]
  162. Wang J. P., Tsao L. T., Raung S. L., Lin C. N. (1997). Investigation of the inhibitory effect of broussochalcone A on respiratory burst in neutrophils. Eur. J. Pharmacol. 320, 201–208. 10.1016/S0014-2999(96)00888-6 [DOI] [PubMed] [Google Scholar]
  163. Wleklik M., Luczak M., Panasiak W., Kobus M., Lammer-Zarawska E. (1988). Structural basis for antiviral activity of flavonoids-naturally occurring compounds. Acta Virol. 32, 522–525. [PubMed] [Google Scholar]
  164. Won S. J., Liu C. T., Tsao L. T., Weng J.-R., Ko H. H., Wang J. P., et al. (2005). Synthetic chalcones as potential anti-inflammatory and cancer chemopreventive agents. Eur. J. Med. Chem. 40, 103–112. 10.1016/j.ejmech.2004.09.006 [DOI] [PubMed] [Google Scholar]
  165. Wu Y. C., Sureshbabu M., Fang Y. C., Wu Y. H., Lan Y. H., Chang F. R., et al. (2013). Potent inhibition of human neutrophil activations by bractelactone, a novel chalcone from Fissistigma bracteolatum. Toxicol. Appl. Pharmacol. 266, 399–407. 10.1016/j.taap.2012.11.021 [DOI] [PubMed] [Google Scholar]
  166. Xie L., Li X. K., Funeshima-Fuji N., Kimura H., Matsumoto Y., Isaka Y., et al. (2009). Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int. Immunopharmacol. 9, 575–581. 10.1016/j.intimp.2009.01.025 [DOI] [PubMed] [Google Scholar]
  167. Xuan N. T., Shumilina E., Gulbins E., Gu S., Götz F., Lang F. (2010). Triggering of dendritic cell apoptosis by xanthohumol. Mol. Nutr. Food. Res. 54, S214–S224. 10.1002/mnfr.200900324 [DOI] [PubMed] [Google Scholar]
  168. Yadav V., Mishra K., Singh D., Mehrotra S., Singh V. (2005). Immunomodulatory effects of curcumin. Immunopharm. Immunot. 27, 485–497. 10.1080/08923970500242244 [DOI] [PubMed] [Google Scholar]
  169. Yeh C. H., Chen T. P., Wu Y. C., Lin Y. M., Lin P. J. (2005). Inhibition of NFκB Activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion 1. J. Surg. Res. 125, 109–116. 10.1016/j.jss.2004.11.009 [DOI] [PubMed] [Google Scholar]
  170. Youssef K. M., El-Sherbeny M. A., El-Shafie F. S., Farag H. A., Al-Deeb O. A., Awadalla S. A.. (2004). Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch. Pharm. 337, 42–54. 10.1002/ardp.200300763 [DOI] [PubMed] [Google Scholar]
  171. Zhang H. G., Kim H., Liu C., Yu S., Wang J., Grizzle W. E., et al. (2007). Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. BBA-Mol. Cell. Res. 1773, 1116–1123. 10.1016/j.bbamcr.2007.04.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Zhang Y., Jiang X., Peng K., Chen C., Fu L., Wang Z., et al. (2014). Discovery and evaluation of novel anti-inflammatory derivatives of natural bioactive curcumin. Drug Des. Dev. Ther. 8, 2161. 10.2147/DDDT.S69914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Zhang Y., Liang D., Dong L., Ge X., Xu F., Chen W., et al. (2015). Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respir. Res. 16, 43. 10.1186/s12931-015-0199-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Zhao C., Yang J., Wang Y., Liang D., Yang X., Li X., et al. (2010). Synthesis of mono-carbonyl analogues of curcumin and their effects on inhibition of cytokine release in LPS-stimulated RAW 264.7 macrophages. Bioorganic Med. Chem. 18, 2388–2393. 10.1016/j.bmc.2010.03.001 [DOI] [PubMed] [Google Scholar]
  175. Zhao C., Zhang Y., Zou P., Wang J., He W., Shi D., et al. (2015). Synthesis and biological evaluation of a novel class of curcumin analogs as anti-inflammatory agents for prevention and treatment of sepsis in mouse model. Drug Des. Devel. Ther. 9, 1663–1678. 10.2147/DDDT.S75862 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Zhou B., Xing C. (2015). Diverse molecular targets for chalcones with varied bioactivities. Med. Chem. 5, 388–404. 10.4172/2161-0444.1000291 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES